AU4869399A - Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) - Google Patents

Description

WO 00/02911 PCT/US99/15592 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (Q-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) GRANT SUPPORT This invention was made with United States Government support under grant number 5 70NANB5HI066 awarded by the National Institute of Standards and Technology. Accordingly, the United States Government has certain rights in the invention. FIELD OF THE INVENTION The present invention is directed to complexes of beta-APP and HsLON proteins. In addition, the present invention relates to the production of antibodies to the aforementioned protein complex, and 10 its use in, inter alia, screening, diagnosis, prognosis and therapy. BACKGROUND OF THE INVENTION 1. p-APP The human beta amyloid precursor (f-APP ) protein has been the subject of intense study since amyloid plaques containing fragments of the p-APP protein represent a key pathophysiological feature 15 in the brains of patients with Alzheimer's Disease (AD) (Glenner and Wong, 1984, Biochem. Biophys. Res. Commun. 120:885-890). The first mRNA for 3-APP was cloned in 1988 (GenBank Accession No. A02759; Mueller-Hill et al., 1988, European Patent Publication EP 276723). This mRNA encodes a neuronally-expressed protein of 695 amino acids. Three other protein precursors of 714, 751, and 770 amino acids are also expressed via differential splicing (Kang and Muller-Hill, 1990, Biochem. Biophys. 20 Res. Commun 166:1192-1200). A main focus of AD research has been the possibility that abnormal processing of p-APP results in products that collect in the brain and form damaging deposits. The principal product in amyloid plaques is p-A4, a 39-42 residue fragment of p-APP located at the start of the C-terminal third of the precursor molecule (Kang et al., 1987, Nature 325:733-736). While this fragment is a normally 25 expressed product in human brain, its accumulation is greatly accelerated in some disorders including AD and trisomy 21 (Suebert et al., 1992, Nature 359:325-327). Mutations in the f-APP gene seem to account for a small percentage of AD cases, and thus, abnormalities of other factors, such as processing enzymes, cofactors, etc., involved in p-A4 folding, stability, or targeting are also likely to account for accelerated accumulation and deposition of f-A4 (Seubert et al., 1993, Nature 361:260-263).

WO 00/02911 PCT/US99/15592 -2 The apolipoprotein E (apoE) protein associates with fp-A4. ApoE may act as a pathological molecular chaperone that binds to soluble p-A4 and stabilizes abnormal f3-pleated sheet formation, and thus, plaque formation (Wisniewski et al., 1992, Neurosci. Lett. 135:235-238). Finally, the presenilin proteins PS-I and PS-2 display a linkage with some cases of early-onset familial AD (Sherrington et al., 5 1995, Nature 375:754-760; Cruts et al., 1996, Hum. Mol. Genet. 5:1449-1455). The results of the above-mentioned studies indicate that abnormal protein-protein interactions of, or functioning of, p-A4, or other products of p-APP, may underlie the pathogenesis of some or all forms of AD. Mitochondrial dysfunction may also be involved in the pathogenesis of AD. A mutation in codon 331 of mitochondrially-encoded subunit 2 of NADH dehydrogenase (complex I of the oxidative 10 phosphorylation chain) has been reported in 10/19 AD patients, and 2/6 patients with amyotrophic lateral sclerosis (ALS) (Lin et al., 1992, Biochem. Biophys. Res. Commun. 182:238-246). Thus, mitochondrial damage is associated with neurodegenerative diseases. A unifying hypothesis regarding the pathogenesis of AD has been formed around the central theme of increased oxidative damage to mitochondria causing disrupted calcium homeostasis and neuronal degeneration (Markesbery, 1997, 15 Free Radic. Biol. Med. 23:134-147; Meier-Ruge and Bertoni-Freddari, 1996, Rev. Neurosci. 7:1-19). Assembly of inner mitochondrial membrane respiratory complexes occurs by addition of mitochondrially-encoded subunits around cores of imported protein subunits (Hall and Hare, 1990, J. Biol. Chem. 265:16484-16490). If assembly is delayed, free mitochondrially-encoded subunits are rapidly degraded in an oligomycin-sensitive manner, thus implicating an ATPase-dependent protease as 20 important to mitochondrial biogenesis, and thus, protection against neurodegenerative disease (Meier-Ruge and Bertoni-Freddari, 1996, Rev. Neurosci. 7:1-19). Thus, mitochondrial dysfunction and the protein components involved therein are implicated along with abnormal 3-APP function in the pathogenesis of AD. 2. HsLON 25 The human Lon-protease-like (HsLON) protein (GenBank Accession No. X74215; Amerik et al., 1994, FEBS Lett. 340:25-28) is the homologue of Lon, an E. coli protease which is involved in the degradation of misfolded proteins. In yeast, the mitochondrially-localized protease PIMI is homologous to Lon, and PIMI and HsLON function interchangeably in yeast to degrade misfolded proteins in the mitochondrial matrix (Suzuki et al., 1994, Science 264:273-276; Teichmann et al., 1996, J. Biol. Chem. 30 271:10137-10142). Yeast expressing mutant PIM] display aberrant assembly of inner mitochondrial membrane respiratory complexes, become respiratory deficient, and ultimately suffer lost integrity of their mitochondrial DNA. Like the yeast homologue, human LON (HsLON) is an ATPase-dependent protease that can function in mitochondrial biogenesis and maintenance (Suzuki et al., 1997, Trends Biochem. Sci. 22:118-123).

WO 00/02911 PCT/US99/15592 -3 HsLON is implicated in all aspects of mitochondrial maintenance and function. As such, it can affect physiological processes including, but not limited to, mitochondrial biogenesis, cell oxidative capacity and energy metabolism, cell apoptosis, calcium homeostasis, and the pathological processes of Alzheimer's Disease (AD), dementia of trisomy 21, amyotrophic lateral sclerosis (ALS), and other 5 neurodegenerative disorders. Further, mutations in mitochondrial DNA, which increase both with age and oxidative stress, are associated with a wide range of both spontaneous and heritable clinical disorders (Odawara, 1996, New Engl. J. Med. 334:270-271; Hammans, 1994, Essays Biochem. 28:99-112). In many, but not all cases, these mutations involve a point mutation at a point mutation "hot spot", (for example, C3254G or A3243T in the mitochondrial tRNA(Leu) gene). However, most 10 disorders are also seen with more generalized mitochondrial DNA deletions (Rose, 1998, Arch. Neurol. 55:17-24). Most of the disorders involve myopathies caused by underlying mitochondrial dysfunction. Among these are MELAS syndrome (Mitochondrial myopathy, Encephalomyopathy, _Lactic Acidosis, and Stroke-like episodes; Saitoh et al., 1998, Neurology, 50:531-534), progressive external 15 ophthalmoplegia (Melberg et al., 1998, Neurology, 50:299-300), both autosomal and non-autosomal cardiomyopathies (Takeda et al., 1996, Diabetes Res. Clin. Pract. 31 Suppl. S123-126), and some forms of polymyalgia rheumatica (Reynier et al., 1994, Biochem. Biophys. Res. Commun. 205:375-380). Many mitochondrial DNA mutations are also associated with CNS degeneration, including Parkinson's disease (Ozawa et al., 1991, Biochem. Biophys. Res. Comm. 177:518-525), Alzheimer's Disease, 20 including morphologically-identified amyloid plaques (Kaido et al., 1996, Acta Neuropath. [Berlin] 92:312-318), and late-onset encephalopathy (Johnston et al., 1995, Ann. Neurol. 37:16-23). Thus, evidence exists that mitochondrial dysfunction, either resulting from mitochondrial DNA mutations, or mitochondrial dysfunction associated with aging, oxidative stress, etc., is associated with neurodegenerative disease. 25 Mitochondrial DNA mutations also underlie diseases and disorders such as MERRF syndrome (Myoclonic Epilepsy with Ragged Red Fibers; Blumenthal et al, 1998, Neurology 50:524-525), multiple symmetric lipomatosis (Klopstock et al., 1997, Mol. Cell. Biochem. 174:271-275), Kearns-Sayre syndrome (pigmented retinopathy, bilateral progressive ophthalmoplegia, and cardiac conduction defects; Zoviani et al., 1988, Neurology 38:1339-1346), male infertility (St. John et al., 1997, Nat. Med. 30 3:124-125), sensorineural hearing loss (Donovan et al., 1995, Ann. Otol. Rhinol. Laryngol. 104:786-792), maternally-inherited deafness (Silvestri et al., 1994, Human Mutat. 3:37-43), and maternally-inherited diabetes (Tsukada et al., 1997, Diabetes Med. 14:1032-1037).

WO 00/029114 PCT/US99/15592 In summary, besides involvement in neurodegenerative disease, HsLON may also be implicated in cardiomyopathy, some forms of diabetes, hearing loss, male infertility, and a number of less common syndromes and disorders associated with mitochondrial DNA mutations. To conclude, both f-APP and HsLON are implicated in neurodegenerative processes and 5 mitochondrial function. As such, each or both can affect physiological processes including, but not limited to, mitochondrial biogenesis, cell oxidative capacity and energy metabolism, cell apoptosis, calcium homeostasis, and pathological processes including, but not limited to, neurodegenerative disorders such as Alzheimer's Disease (AD), dementia of trisomy 21, Parkinson's disease, amyotrophic lateral sclerosis (ALS); cardiomyopathy; some forms of diabetes; hearing loss; and male infertility; as 10 well as a number of less common syndromes and disorders that are associated with mitochondrial DNA mutations. p-APP and HsLON have been described to be involved in similar processes, however no direct association or interaction of p-APP with HsLON has been described previously to the present invention. Citation or identification of any reference in this application shall not be construed as an 15 admission that such reference is available as prior art to the present invention. SUMMARY OF THE INVENTION The present invention is based, in part, on the discovery of a novel interaction between p-amyloid precursor protein (p-APP ) and the HsLON protein, in particular, interaction between the predominantly expressed 695 amino acid form of p-APP, (to which the term p-APP refers in this 20 Application), or the portion of p-APP comprised of residues 597-638, (herein referred to as p-A4), and HsLON, or the C-terminal 126 residues of HsLON. The present invention is directed to certain compositions comprising and methods for production of protein complexes of 1-APP with a protein that interacts with (i.e., binds to) p-APP. Specifically, the invention is directed to complexes of p-APP, and derivatives, fragments and analogs of 1-APP, with 25 HsLON, and its derivatives, fragments and analogs (a complex of p-APP and HsLON is designated as p-APP:HsLON herein). The present invention is further directed to methods of screening for proteins that interact with p-APP and/or HsLON, or with derivatives, fragments or analogs of p-APP and/or HsLON. Methods for production of the p-APP:HsLON complex, and derivatives and analogs of the 30 complex and/or individual proteins, e.g., by recombinant means, are also provided. Pharmaceutical compositions are also provided.

WO 00/02911 PCTIUS99/15592 -5 The invention is further directed to methods for modulating (i.e., inhibiting or enhancing) the activity of a f-APP:HsLON complex. The protein components of a p-APP:HsLON complex have been implicated in physiological processes including, but not limited to, mitochondrial biogenesis, cell oxidative capacity and energy metabolism, cell apoptosis, calcium homeostasis, and pathological 5 processes including, but not limited to, neurodegenerative disorders such as Alzheimer's Disease, dementia of trisomy 21, Parkinson's disease, amyotrophic lateral sclerosis (ALS); cardiomyopathy; some forms of diabetes; hearing loss; and male infertility; as well as a number of less common syndromes and disorders associated with mitochondrial DNA mutations. Accordingly, the present invention is directed to methods for screening p-APP:HsLON complexes, as well as derivatives and analogs of the 10 fp-APP:HsLON complex, for the ability to alter a cell function, particularly a cell function in which 3-APP and/or HsLON has been implicated, as non-exclusively listed, supra. The present invention is also directed to therapeutic and prophylactic, as well as diagnostic, prognostic, and screening methods and compositions based upon the p-APP:HsLON complex (and the nucleic acids encoding the individual proteins that participate in the complex). Therapeutic compounds 15 of the invention include, but are not limited to, a p-APP:HsLON complex, and a complex where one or both members of the complex is a derivative, fragment, homolog or analog of p-APP or HsLON; antibodies to and nucleic acids encoding the foregoing; and antisense nucleic acids to the nucleotide sequences encoding the complex components. Diagnostic, prognostic and screening kits are also provided. 20 Animal models and methods of screening for modulators (i.e., agonists, and antagonists) of the activity of a p-APP:HsLON complex are also provided. Methods of identifying molecules that inhibit, or alternatively, that increase formation of a p-APP:HsLON complex are also provided. BRIEF DESCRIPTION OF THE DRAWINGS 25 Figure 1. The nucleotide sequence of f-APP (GenBank Accession No. A02759 (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO:2). The coding sequence beginning at base 1935 (amino acid 597), marked by arrow "A", and ending at base 2060 (amino acid 638), marked by arrow "B", was used as bait in the assays described infra. Figure 2. The nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4) of 30 human HsLON (GenBank Accession No. X74215). The 5' start site of the identified prey sequence was at base 2194 (amino acid 721), marked by arrow "A".

WO 00/02911 PCT/US99/15592 -6 Figure 3. Demonstration of the specificity of the [p-APP:HsLON interaction. A positive interaction for a bait and prey proteins is indicated as "+" in the box forming the intersection between the particular bait and prey proteins, a lack of interaction is designated by "-". The intersection of the [-APP column with the HsLON row indicates growth (Box A) (i.e., a positive interaction). In contrast, 5 the intersection of the p-APP column with the rows for PI-P5, and the intersection of the HsLON row with columns for B1--B6, indicates no growth, i.e., no protein interaction. These data demonstrate the specificity of the f3-APP:HsLON interaction. DETAILED DESCRIPTION OF THE INVENTION The present invention is based, in part, upon identification of proteins that interact with [-APP 10 (SEQ ID NOS:2) using a modified form of the yeast matrix mating test. At least amino acids 721 to 845 of HsLON (SEQ ID NOS:4) were found to form a complex under physiological conditions with at least amino acids 597 to 638 of [p-APP (SEQ ID NOS:2) (the complex of [p-APP with HsLON is indicated as" [p-APP:HsLON" herein). The -APP:HsLON complex, by virtue of the interaction, is implicated in modulating the functional activities of [-APP and its binding partner. Such functional activities include 15 physiological processes including, but not limited to, neurodegenerative disorders such as Alzheimer's Disease, dementia of trisomy 21, Parkinson's disease, amyotrophic lateral sclerosis (ALS); cardiomyopathy; some forms of diabetes; hearing loss; and male infertility; as well as a number of less common syndromes and disorders associated with mitochondrial DNA mutations. The present invention is also directed to methods of screening for proteins that interact with, 20 e.g., bind to [-APP. The present invention further discloses a complex of the [-APP protein, or a derivative, analog or fragment thereof, in particular with HsLON protein, or a derivative, analog or fragment thereof. In a preferred embodiment, such complex binds an anti-p[-APP, anti-HsLON, and/or anti-[p-APP:HsLON complex antibody. In another specific embodiment of the present invention, a complex of human [-APP with human HsLON is provided. 25 The present invention also provides methodologies for the production and/or isolation of p-APP:HsLON complex. In a specific embodiment, the present invention provides methodology of using recombinant DNA techniques to express both [3-APP and HsLON (or a derivative, fragment or analog of one or both members of the complex) wherein both binding partners are under the control of one heterologous promoter (i.e., a promoter not naturally associated with the gene encoding the 30 particular complex component) or where each is under the control of a separate heterologous promoter. Methods of diagnosis, prognosis, and screening for diseases and disorders associated with aberrant levels of a P-APP:HsLON complex are discloses. The present invention also provides WO 00/02911 PCT/US99/15592 -7 methodology for the treatment or prevention of diseases or disorders associated with an aberrant level of p-APP:HsLON complex, or an aberrant level of activity of one or more of the components of the complex, by administration of a f-APP:HsLON complex, or modulators of B-APP:HsLON complex activity or formation (e.g., antibodies that bind to a f3-APP:HsLON complex), or non-complexed P-APP 5 or its binding partner or a derivative, fragment, analog or homolog thereof. Preferably, the aforementioned derivative, fragment, analog or homolog contains: (i) the portion of f3-APP or HsLON that is directly involved in complex formation; (ii) mutants of p-APP or of HsLON that modulate binding affinity; (iii) small molecule inhibitors or enhancers of complex formation; or (iv) antibodies that either stabilize or neutralize the complex, and the like. 10 Methodologies of assaying p-APP:HsLON complex for biological activity as a therapeutic or diagnostic, as well as methodologies for screening for p-APP:HsLON complex or modulators thereof (i.e., agonists and antagonists), are also disclosed herein. For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the following subsections. 15 (1) The p-APP protein, the HsLON protein and the p-APP:HsLON complex The present invention discloses the complex of p-APP with HsLON (the p-APP:HsLON complex). In a preferred embodiment, the p-APP:HsLON complex is a complex of human proteins. The present invention also relates to: (i) complexes of derivatives, fragments and analogs of the 3-APP with a HsLON; (ii) complexes of the p-APP with derivatives, fragments and analogs of HsLON and (iii) 20 complexes of derivatives, fragments and analogs of the 13-APP and HsLON. It should be noted that, as used herein, fragment, derivative or analog of a p-APP:HsLON complex includes complexes where one or both members of the complex are fragments, derivatives or analogs of the wild-type p-APP or HsLON protein. Derivatives, fragments, and analogs provided herein are defined as sequences of at least 6 25 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively. Fragments are, at most, one nucleic acid-less or one amino acid-less than the wild type full length sequence. Derivatives and analogs may be full length or other than full length, if said derivative or analog contains a modified nucleic acid or amino acid, as described infra. Derivatives or 30 analogs of P-APP and HsLON include, but are not limited to, molecules comprising regions that are substantially homologous to p-APP or HsLON, in various embodiments, by at least about 30%, 50%, 70%, 80%, or 90% identity (with a preferred identity of 80-95%) over an amino acid sequence of WO 00/02911 PCT/US99/15592 -8 identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, for e.g., Wisconsin GCG (Genetics Computer Group) software package using default parameter settings. Alternatively, comparison may be made to an aligned sequence whose encoding nucleic acid is capable of hybridizing to the complement (e.g., the inverse 5 complement) of a sequence encoding [-APP or HsLON under stringent (the preferred embodiment), moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and infra. Preferably, as disclosed by the present invention, the [p-APP:HsLON complex in which one or both members of the complex are a fragment, derivative or analog of the wild-type protein are 10 functionally active [p-APP:HsLON complex. In particular aspects, the native proteins (or homologs, fragments, derivatives or analogs thereof) of the p-APP and/or HsLON are of insects (e.g., fly), plants, or animals (e.g., mouse, rat, pig, cow, dog, monkey, frog) or, most preferably, human. As utilized herein, the term "functionally active [3-APP:HsLON complex" refers to species displaying one or more known functional attributes of a full-length p-APP (or derivatives, fragments, analogs or homologs 15 thereof), complexed with full-length HsLON (or derivatives, fragments, analogs or homologs thereof), including, but not exclusive to, the control of cell cycle progression, cellular differentiation and apoptosis, intracellular signal transduction, neurogenesis, response to viral infection, a hyperproliferative disorder such as tumorigenesis and tumor spread, a degenerative disorder such as a neurodegenerative disease, autoimmune disease, a disorder associated with organ transplantation, inflammatory and/or 20 allergic disease, atherosclerosis, nephropathy, cardiac disease, muscle disease, or the like. Specific embodiments of the present invention disclose the p-APP:HsLON complex comprised of fragments of one or both protein species of the complex. In a preferred embodiment, these aforementioned fragments may consist of, but are not limited to, fragments of HsLON that have been identified as interacting with the p-APP in an improved, modified yeast two hybrid assay in this 25 invention, i.e., amino acids 721-845 of HsLON as depicted in Figure 2 [SEQ ID NO:4]. In addition, fragments (or proteins comprising fragments) that may lack some or all of the aforementioned regions of either member of the complex, as well as nucleic acids that encode the aforementioned proteins, are also disclosed herein. The nucleotide sequences encoding human [3-APP and human HsLON are known, (GenBank 30 Accession No. A02759 and GenBank Accession No. X74215, respectively), and are disclosed in Figures I and 2 (SEQ ID NOS: 1 and 3, respectively). Nucleic acids may be obtained by any method known within the art (e.g., by PCR amplification using-synthetic primers hybridizable to the 3'- and 5'-termini of the sequence and/or by cloning from a cDNA or genomic library using an oligonucleotide sequence specific for the given gene sequence, or the like).

WO 00/02911 PCT/US99/15592 -9 Homologs (i.e., nucleic acids encoding the aforementioned proteins derived from species other than human) or other related sequences (e.g., paralogs) can also be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning. 5 In a most preferred embodiment, a nucleic acid sequence that is hybridizable to a nucleic acid sequence (or a complement of the foregoing) encoding fp-APP and/or HsLON, or a derivative of the same, under conditions of high stringency is provided. By way of example and not limitation, procedures using such conditions of high stringency are as follows: Step 1: Filters containing DNA are pretreated for 8 hours to overnight at 65'C in buffer composed of 6X SSC, 50 mM Tris-HCI (pH 7.5), 1 10 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 pg/ml denatured salmon sperm DNA. Step 2: Filters are hybridized for 48 hours at 65'C in the above prehybridization mixture to which is added 100 pg/ml denatured salmon sperm DNA and 5-20 x 106 cpm of 2 P-labeled probe. Step 3: Filters are washed for 1 hour at 37'C in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50'C for 45 minutes. Step 4: Filters are autoradiographed. 15 Other conditions of high stringency that may be used are well known in the art. See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY. In a second embodiment, a nucleic acid sequence that is hybridizable to a nucleic acid sequence (or a complement of the foregoing) encoding p-APP and/or HsLON, or a derivative of either, under 20 conditions of moderate stringency is provided. By way of example and not limitation, procedures using such conditions of moderate stringency are as follows: Step 1: Filters containing DNA are pretreated for 6 hours at 55 0 C in a solution containing 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 pg/ml denatured salmon sperm DNA. Step 2: Filters are hybridized for 18-20 hours at 55 0 C in the same solution with 5-20 x 106 cpm 32 P-labeled probe added. Step 3: Filters are washed at 37'C for 1 hour in a 25 solution containing 2X SSC, 0.1% SDS, then washed twice for 30 minutes at 60'C in a solution containing IX SSC and 0.1% SDS. Step 4: Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency that may be used are well-known in the art. See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY. 30 In a third embodiment, a nucleic acid that is hybridizable to a f-APP and/or HsLON nucleic acid sequence or to a nucleic acid sequence encoding a fp-APP and/or HsLON derivative (or a complement of the foregoing), under conditions of low stringency, is provided. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. NatL. Acad. Sci. USA 78: 6789-6792): Step 1: Filters containing DNA are pretreated for 6 hours at WO 00/02911 PCT/US99/15592 -10 40'C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 ptg/ml denatured salmon sperm DNA. Step 2: Filters are hybridized for 18-20 hours at 40'C in the same solution with the addition of 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ptg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 x 106 cpm 5 1 2 P-labeled probe. Step 3: Filters are washed for 1.5 hours at 55 0 C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60 0 C. Step 4: Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68'C and reexposed to film. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for 10 cross-species hybridizations). See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY. The invention also relates to nucleic acids hybridizable to or complementary to the foregoing sequences, in particular the invention provides the inverse complement to nucleic acids hybridizable to 15 the foregoing sequences (i.e., the inverse complement of a nucleic acid strand has the complementary sequence running in reverse orientation to the strand so that the inverse complement would hybridize with little or no mismatches to the nucleic acid strand). In specific aspects, nucleic acid molecules are provided that comprise a sequence complementary to (specifically, are the inverse complement of) at least about 10, 25, 50, 100, or 200 nucleotides or the entire coding region of a p-APP and/or HsLON 20 gene (SEQ ID NOS: I and 3, respectively). Nucleic acid molecules encoding derivatives and analogs of p-APP and/or HsLON (supra), or antisense nucleic acids to the same (see, e.g., infra) are additionally provided. Within nucleotide sequences encoding polypeptides identified as beta APP interactants via the modified yeast two hybrid assay in this invention, potential open reading frames can be identified using 25 the NCBI BLAST program ORF Finder available to the public. Because all known protein translation products are at least 60 amino acids or longer (Creighton, 1992, PROTEINS, 2nd Ed., W.H. Freeman and Co., New York), only those ORFs potentially encoding a protein of 60 amino acids or more are considered. If an initiation methionine codon (ATG) and a translational stop codon (TGA, TAA, or TAG) are identified, then the boundaries of the protein are defined. Other potential proteins include any 30 open reading frames that extend to the 5' end of the nucleotide sequence, in which case the open reading frame predicts the C-terminal or core portion of a longer protein. Similarly, any open reading frame that extends to the 3' end of the nucleotide sequence predicts the N-terminal portion of a longer protein.

WO 00/02911 PCT/US99/15592 -11 Recombinant Technologies for obtaining the complex or 1-APP or HsLON The p-APP and HsLON protein, either alone or within a complex, may be obtained by methods well-known in the art for protein purification and recombinant protein expression. For recombinant expression of one or more of the proteins, the nucleic acid containing all or a portion of the nucleotide 5 sequence encoding the protein may be inserted into an appropriate expression vector (i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence). In a preferred embodiment, the regulatory elements are heterologous (i.e., not the native gene promoter). Alternately, the necessary transcriptional and translational signals may also be supplied by the native promoter for the p-APP or any HsLON genes and/or their flanking regions. 10 A variety of host-vector systems may be utilized to express the protein coding sequence(s). These include, but are not limited to: (i) mammalian cell systems that are infected with vaccinia virus, adenovirus, and the like; (ii) insect cell systems infected with baculovirus and the like; (iii) yeast containing yeast vectors or (iv) bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. Depending upon the host-vector system utilized, any one of a number of suitable transcription 15 and translation elements may be used. In a preferred embodiment, the p-APP:HsLON complex are obtained by expressing the entire p-APP coding sequence and a HsLON coding sequence within the same cell, either under the control of the same promoter or two separate promoters. In another embodiment, a derivative, fragment or homolog of the p-APP and/or a derivative, fragment or homolog of a HsLON are recombinantly 20 expressed. Preferably, the derivative, fragment or homolog of the 1-APP and/or the HsLON protein form a complex with a binding partner that has been identified by a binding assay (e.g., the modified yeast two hybrid system assay) and, more preferably, form a complex that binds to an anti-p-APP, anti-HsLON and/or anti- p-APP:HsLON complex antibody. Any of the methodologies known within the relevant prior art regarding the insertion of nucleic 25 acid fragments into a vector may be utilized to construct expression vectors that contain a chimeric gene comprised of the appropriate transcriptional/translational control signals and protein-coding sequences. These methodologies may include, but are not limited to, in vitro recombinant DNA and synthetic techniques, as well as in vivo recombination techniques (e.g., genetic recombination). The expression of nucleic acid sequences that encode the 13-APP and the HsLON protein, or derivatives, fragments, analogs 30 or homologs thereof, may be regulated by a second nucleic acid sequence such that the genes or fragments thereof are expressed in a host that has been concomitantly transformed with the recombinant DNA molecule(s) of interest. The expression of the specific proteins may be controlled by any promoter/enhancer known in the art including, but not limited to: (i) the SV40 early promoter (see e.g., WO 00/02911 PCT/US99/15592 -12 Bernoist & Chambon, 1981. Nature 290: 304-3 10); (ii) the promoter contained within the 3'-terminus long terminal repeat of Rous Sarcoma Virus (see e.g., Yamamoto, et al., 1980. Cell 22: 787-797); (iii) the Herpesvirus thymidine kinase promoter (see e.g., Wagner, et al., 1981. Proc. NatL. A cad. Sci. USA 78: 1441-1445); (iv) the regulatory sequences of the metallothionein gene (see e.g., Brinster, et al., 1982. 5 Nature 296: 39-42); (v) prokaryotic expression vectors such as the p-lactamase promoter (see e.g., Villa-Kamaroff, et al., 1978. Proc. NatL. Acad. Sci. USA 75: 3727-373 1); (vi) the tac promoter (see e.g., DeBoer, et al., 1983. Proc. Nat?. Acad Sci. USA 80: 21-25) and the like. In addition, plant promoter/enhancer sequences within plant expression vectors may also be utilized including, but not limited to: (i) the nopaline synthetase promoter (see e.g., Herrar-Estrella, et 10 al., 1984. Nature 303: 209-213); (ii) the cauliflower mosaic virus 35S RNA promoter (see e.g., Garder, et al., 1981. Nuc. Acids Res. 9: 2871) and (iii) the promoter of the photosynthetic enzyme ribulose bisphosphate carboxylase (see e.g., Herrera-Estrella, et aL., 1984. Nature 310: 115-120) and the like. Promoter/enhancer elements from yeast and other fungi (e.g., the Gal4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter), as 15 well as from animal transcriptional control regions, for example, those that possess tissue specificity and have been used in transgenic animals, may be utilized in the production of proteins of the present invention. Transcriptional control sequences derived from animals include, but are not limited to: (i) the insulin gene control region active within pancreatic f3-cells (see e.g., Hanahan, et al., 1985. Nature 315: 115-122); (ii) the immunoglobulin gene control region active within lymphoid cells (see e.g., 20 Grosschedl, et al., 1984. Cell 38: 647-658); (iii) the albumin gene control region active within liver (see e.g., Pinckert, et al., 1987. Genes and Devel. 1: 268-276; (iv) the myelin basic protein gene control region active within brain oligodendrocyte cells (see e.g., Readhead, et al., 1987. Cell 48: 703-712); and (v) the gonadotrophin-releasing hormone gene control region active within the hypothalamus (see e.g., Mason, et al., 1986. Science 234: 1372-1378), and the like. 25 In a specific embodiment of the present invention, a vector is utilized that comprises a promoter that is operably-linked to nucleic acid sequences that encode p-APP and/or HsLON, or a fragment, derivative or homolog, thereof, one or more origins of replication, and optionally, one or more selectable markers (e.g., an antibiotic resistance gene). In a preferred embodiment, a vector is utilized that is comprised of a promoter operably-linked to nucleic acid sequences encoding both p-APP and HsLON, 30 one or more origins of replication, and, optionally, one or more selectable markers. In another specific embodiment, an expression vector contains the coding sequences (or portions thereof) of 3-APP and HsLON, either together or separately. The expression vector may be generated by subcloning the aforementioned gene sequences into the EcoRI restriction site of each of the three WO 00/02911 PCT/US99/15592 -13 available pGEX vectors (glutathione S-transferase expression vectors; see e.g., Smith & Johnson, 1988. Gene 7: 31-40), thus allowing the expression of products in the correct reading frame. Expression vectors that contain sequences of interest may be identified by three general approaches: (i) nucleic acid hybridization, (ii) presence or absence of "marker" gene function and/or (iii) 5 expression of the inserted sequences. In a first approach, p-APP and HsLON may be detected by nucleic acid hybridization using probes comprising sequences homologous and complementary to the inserted sequences of interest. In a second approach, the recombinant vector/host system may be identified and selected based upon the presence or absence of certain "marker" functions (e.g., binding to an antibody specific for p-APP, HsLON, or a fp-APP:HsLON complex, resistance to antibiotics, occlusion-body 10 formation in baculovirus, and the like) caused by the insertion of the sequences of interest into the vector. In a third approach, recombinant expression vectors may be identified by assaying for the expression of the p-APP concomitantly with expression of HsLON by the recombinant vector. Once the recombinant (3-APP and HsLON molecules have been identified and the complex or individual proteins isolated, and a suitable host system and growth conditions have been established, the 15 recombinant expression vectors may be propagated and amplified in-quantity. As previously discussed, expression vectors or their derivatives that can be used include, but are not limited to, human or animal viruses (e.g., vaccinia virus or adenovirus); insect viruses (e.g., baculovirus); yeast vectors; bacteriophage vectors (e.g., lambda phage); plasmid vectors and cosmid vectors, and the like. A host cell strain may be selected that modulates the expression of inserted sequences of 20 interest, or modifies or processes expressed proteins encoded by said sequences in the specific manner desired. In addition, expression from certain promoters may be enhanced in the presence of certain inducers in a selected host strain; thus facilitating control of the expression of a genetically-engineered p-APP and/or HsLON. Moreover, different host cells possess characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, 25 phosphorylation, and the like) of expressed proteins. Appropriate cell lines or host systems may thus be chosen to ensure the desired modification and processing of the foreign protein is achieved. For example, protein expression within a bacterial system can be used to produce an unglycosylated core protein; whereas expression within mammalian cells ensures "native" glycosylation of a heterologous protein. 30 In other specific embodiments, (-APP and/or HsLON (or derivatives, fragments, analogs and homologs thereof) may be expressed as fusion or chimeric protein products comprising the protein joined via a peptide bond to a heterologous protein sequence of a different protein. Such chimeric products may be produced by ligating together appropriate nucleic acid sequences that encode desired WO 00/02911 -14- PCTIUS99/15592 amino acids, said ligation retaining the proper coding frames, and subsequently expressing the chimeric products in a suitable host by methods well known in the art. Alternatively, such a chimeric product can be made by protein synthetic techniques (e.g., by use of a peptide synthesizer). A specific embodiment of the present invention discloses a chimeric protein comprising a 5 fragment of p-APP and/or HsLON. In another specific embodiment, fusion proteins are provided that contain the interacting domains of p-APP and HsLON (the domains involved in the direct formation of p-APP:HsLON complex) and, optionally, have a heterofunctional reagent (e.g., a peptide linker) that serves to both link the two aforementioned proteins and to promote the interaction of fp-APP and HsLON binding domains. These fusion proteins may be particularly useful where the stability of the interaction 10 is desirable (i.e., stability due to the formation of the complex as an intramolecular reaction), for example in production of antibodies specific to 13-APP:HsLON complex. In a specific embodiment of the present invention, the nucleic acids encoding proteins, and proteins consisting of or comprising a fragment of 1-APP or HsLON that consists of a minimum of 6 contiguous amino acid residues of 13-APP and/or HsLON, are provided herein. In another embodiment, 15 the aforementioned protein fragment is comprised of at least 10, 20, 30, 40, or 50 amino acid residues (and preferably not larger that 35, 100 or 200 amino acid residues) of 1-APP or HsLON. Derivatives or analogs of 13-APP and HsLON include, but are not limited to, molecules comprising regions that are substantially homologous to p-APP or HsLON in various embodiments, of at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or preferably 95% amino acid identity when: (i) compared to an amino acid 20 sequence of identical size; (ii) compared to an aligned sequence in that the alignment is done by a computer homology program known within the art or (iii) the encoding nucleic acid is capable of hybridizing to a sequence encoding p-APP or HsLON under stringent (preferred), moderately stringent, or non-stringent conditions (see, e.g., supra). p-APP and/or HsLON derivatives may be produced by alteration of their sequences by 25 substitutions, additions or deletions that result in functionally-equivalent molecules. In a specific embodiment of the present invention, the degeneracy of nucleotide coding sequences allows for the use of other DNA sequences that encode substantially the same amino acid sequence as 1-APP or HsLON genes. In another specific embodiment, one or more amino acid residues within the sequence of interest may be substituted by another amino acid of a similar polarity and net charge, thus resulting in a silent 30 alteration. Conservative amino acid substitution variants for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, WO 00/02911 PCT/US99/15592 -15 tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine, lysine and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. p-APP or HsLON derivatives and analogs of the present invention may be produced by various methodologies known within the art. For example, the cloned p-APP and HsLON gene sequences may 5 be modified by any of numerous methods known within the art. See e.g., Sambrook, et al., 1990. Molecular Cloning: A Laboratory Manual, 2nd ed., (Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY). These sequences may be digested at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification, if so desired, and the resultant fragments isolated and ligated in vitro. Additionally, 1-APP- or HsLON-encoding nucleic acids may be mutated in vitro or in 10 vivo to: (i) create variations in coding regions; (ii) create and/or destroy translation, initiation, and/or termination sequences; and/or (iii) form new restriction endonuclease sites or destroy pre-existing ones, so as to facilitate further in vitro modification. Any technique for mutagenesis known within the art may be utilized, including but not limited to, chemical mutagenesis and in vitro site-directed mutagenesis (see e.g., Hutchinson, et al., 1978. J. Biol. Chem 253: 6551-6558); use of TABJ- linkers (Pharmacia), 15 and other similar methodologies. Isolation and analysis of the gene product or complex Once a recombinant cell expressing p-APP and/or HsLON, or a fragment, analog, or derivative thereof, is identified, the individual gene product or complex may be isolated and analyzed. This is achieved by assays that are based upon the physical and/or functional properties of the protein or 20 complex, including, but not limited to, radioactive labeling of the product followed by analysis by gel electrophoresis, immunoassay, cross-linking to marker-labeled products, and the like. The p-APP:HsLON complex may be isolated and purified by standard methods known in the art (either from natural sources or recombinant host cells expressing the proteins/protein complex) including, but not limited to, column chromatography (e.g., ion exchange, affinity, gel exclusion, reverse-phase, high 25 pressure, fast protein liquid, etc), differential centrifugation, differential solubility, or similar methodologies used for the purification of proteins. Alternatively, once 1-APP or HsLON or its derivative is identified, the amino acid sequence of the protein can be deduced from the nucleic acid sequence of the chimeric gene from which it was encoded. Hence, the protein or its derivative can be synthesized by standard chemical methodologies known in the art. See, e.g., Hunkapiller, et al., 1984. 30 Nature 310: 105-111. In a specific embodiment, a p-APP:HsLON complex (whether produced by recombinant DNA techniques, chemical synthesis methods, or by purification from native sources) is made up from proteins, fragments, analogs and derivatives thereof, that, as their primary amino acid, contain sequences WO 00/02911 -16- PCTIUS99/15592 substantially as depicted in Figures 1 (SEQ ID NO:2) and 2 (SEQ ID NO:4), as well as proteins homologous thereto. Manipulations of the 3-APP and/or HsLON sequences Manipulations of the p-APP and/or HsLON sequences may be made at the protein level. 5 Included within the scope of the present invention are complex of the p-APP or HsLON fragments, derivatives, fragments or analogs that are differentially modified during or after translation (e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, and the like). Any of the numerous chemical modification methodologies known within the art may be utilized including, 10 but not limited to, specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH 4 , acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc. In a specific embodiment, the [-APP and/or HsLON sequences are modified to include a fluorescent label. In another specific embodiment, the p-APP and/or the HsLON are modified by the incorporation of a heterofunctional reagent, wherein such heterofunctional reagent may be used to 15 cross-link the members of the complex. Chemical synthesis Complexes of analogs and derivatives of [3-APP and/or HsLON can be chemically synthesized. For example, a peptide corresponding to a portion of p-APP and/or HsLON that comprises the desired domain or that mediates the desired activity in vitro (e.g., p-APP:HsLON complex formation), may be 20 synthesized by use of a peptide synthesizer. In cases where natural products are suspected of being mutant or are isolated from new species, the amino acid sequence of P-APP and/or HsLON isolated from the natural source, as well as those expressed in vitro, or from synthesized expression vectors in vivo or in vitro, may be determined from analysis of the DNA sequence, or alternatively, by direct sequencing of the isolated protein. The [p-APP:HsLON complex may also be analyzed by hydrophilicity analysis 25 (see e.g., Hopp & Woods, 1981. Proc. Natl. Acad. Sci. USA 78: 3824-3828) that can be utilized to identify the hydrophobic and hydrophilic regions of the proteins, thus aiding in the design of substrates for experimental manipulation, such as in binding experiments, antibody synthesis, etc. Secondary structural analysis may also be performed to identify regions of the [-APP and/or HsLON that assume specific structural motifs. See e.g., Chou & Fasman, 1974. Biochem. 13: 222-223. Manipulation, 30 translation, secondary structure prediction, hydrophilicity and hydrophobicity profiles, open reading frame prediction and plotting, and determination of sequence homologies, can be accomplished using computer software programs available in the art, for e.g., Wisconsin GCG (Genetics Computer Group) software package using default parameter settings. Other methods of structural analysis including, but WO 00/02911 PCT/US99/15592 -17 not limited to, X-ray crystallography (see e.g., Engstrom, 1974. Biochem. Exp. Biol. 11: 7-13); mass spectroscopy and gas chromatography (see e.g., METHODS IN PROTEIN SCIENCE, 1997. J. Wiley and Sons, New York, NY) and computer modeling (see e.g., Fletterick & Zoller, eds., 1986. Computer Graphics and Molecular Modeling, In: CURRENT COMMUNICATIONS IN MOLECULAR BIOLOGY, Cold 5 Spring Harbor Laboratory Press, Cold Spring Harbor, NY) may also be employed. Methodologies for screening The present invention provides methodologies for screening p-APP, HsLON, and/or p-APP:HsLON complexes, as well as derivatives, fragments and analogs thereof, for the ability to alter and/or modulate cellular functions, particularly those functions in which 13-APP and/or HsLON have 10 been implicated. These functions include, but are not limited to, control of cell-cycle progression; regulation of transcription; control of intracellular signal transduction; and pathological processes, as well as various other biological activities (e.g., binding to an anti-p-APP, anti-HsLON, and/or anti-p3-APP:HsLON complex antibody, and the like). The derivatives, fragments or analogs that possess the desired immunogenicity and/or antigenicity may be utilized in immunoassays, for immunization, for 15 inhibition of p-APP, HsLON, and/or p-APP:HsLON complex activity, etc. For example, derivatives, fragments or analogs that retain, or alternatively lack or inhibit, a given property of interest (e.g., participation in a 13-APP:HsLON complex) may be utilized as inducers, or inhibitors, respectively, of such a property and its physiological correlates. In a specific embodiment, a p-APP:HsLON complex of a fragment of the p-APP and/or a fragment of HsLON that can be bound by an anti-p-APP and/or 20 anti-HsLON antibody or antibody specific for a p-APP:HsLON complex when such a fragment is included within a given P-APP:HsLON complex. Derivatives, fragments and analogs of p-APP:HsLON complex may be analyzed for the desired activity or activities by procedures known within the art. (2) Production of antibodies to the p-APP:HsLON complex As disclosed by the present invention herein, p-APP:HsLON complex, or derivatives, fragments, 25 analogs or homologs thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and an Fab expression library. In a specific embodiment, antibodies to a complex of human p-APP and human HsLON are disclosed. In another specific embodiment, complex formed from fragments of p-APP and HsLON; wherein these fragments 30 contain the protein domain that interacts with the other member of the complex and are used as immunogens for antibody production. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies to a p-APP:HsLON complex, or derivative, fragment, analog or homolog thereof.

WO 00/02911 PCT/US99/15592 -18 For the production of polyclonal antibodies, various host animals may be immunized by injection with the native f-APP:HsLON complex, or a synthetic variant thereof, or a derivative of the foregoing (e.g., a cross-linked f-APP:HsLON). Various adjuvants may be used to increase the immunological response and include, but are not limited to, Freund's (complete and incomplete), mineral 5 gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.) and human adjuvants such as Bacille Calmette-Guerin and Corynebacterium parvum. For preparation of monoclonal antibodies directed towards a fp-APP:HsLON complex, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of 10 antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma technique (see Kohler & Milstein, 1975. Nature 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983. Immunol. Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985. In: Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Human monoclonal 15 antibodies may be utilized in the practice of the present invention and may be produced by the use of human hybridomas (see Cote, et al., 1983. Proc. Nat?. Acad Sci. USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985. In: Monoclonal Antibodies and Cancer Therapy (Alan R. Liss, Inc., pp. 77-96). According to the invention, techniques can be adapted for the production of single-chain 20 antibodies specific to p-APP:HsLON complex (see e.g., U.S. Patent No. 4,946,778). In addition, methodologies can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989. Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for p-APP:HsLON or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be "humanized" by techniques well known in the art. See e.g., U.S. Patent 25 No. 5,225,539. Antibody fragments that contain the idiotypes to -APP:HsLON complex may be produced by techniques known in the art including, but not limited to: (i) an F(ab') 2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab'>2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments. 30 In one embodiment, methodologies for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of p-APP:HsLON complex is facilitated by generation of hybridomas that bind to the fragment of f3-APP:HsLON complex possessing such a domain. In WO 00/02911 PCTIUS99/15592 -19 another specific embodiment, methodologies for the selection of an antibody that specifically binds a fp-APP:HsLON complex but that does not specifically bind to the individual proteins of fp-APP:HsLON complex (identified by selecting the antibody on the basis of positive-binding to j-APP:HsLON complex with a concomitant lack of binding to the individual p-APP and HsLON protein) are within the 5 scope of the invention. Accordingly, antibodies that are specific for a domain within p-APP:HsLON complex, or derivative, fragments, analogs or homologs thereof, are also provided herein. It should be noted that the aforementioned antibodies may be used in methods known within the art relating to the localization and/or quantitation of p-APP:HsLON complex (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in 10 imaging the protein, and the like). In a given embodiment, anti-3-APP, anti-HsLON, and/or anti- P-APP:HsLON complex antibodies, or derivatives, fragments, analogs or homologs thereof that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds [hereinafter "Therapeutics"]. (3) Use of p-APP:HsLON Complex in Diagnosis, Prognosis and Screening 15 p-APP:HsLON complex may serve as a "marker" for specific disease states that involve the disruption of physiological processes in which p-APP and HsLON are known to be involved. See, e.g., BACKGROUND OF THE INVENTION. Such functional activities include, but not limited to, (1) neurodegenerative disorders such as Alzheimer's Disease, dementia of trisomy 21, Parkinson's disease, amyotrophic lateral sclerosis (ALS); (2) cardiomyopathy; (3) some forms of diabetes; 20 (4) hearing loss; (5) and male infertility; as well as (6) a number of less common syndromes and disorders associated with mitochondrial DNA mutations, and the like. Thus p-APP:HsLON complexes are predicted to have diagnostic utility. Therefore, the differentiation and classification of particular groups of patients possessing elevations or deficiencies of a p-APP:HsLON complex may lead to new nosological classifications of diseases, thereby markedly advancing diagnostic ability. 25 The detection of levels of f-APP:HsLON complex or levels of p-APP and/or HsLON protein, or detection of levels of mRNAs that encode the components of a p-APP:HsLON complex, may be utilized in the analysis of various diseases, and may provide critical information in various medical processes, including: diagnosis, prognosis, identifying disease states, following a disease course, following the efficacy of an administered therapeutics, following therapeutic response, and the like. Similarly, both 30 the nucleic acid sequences (and sequences complementary thereto) and antibodies specific to 13-APP:HsLON complex and/or the individual components that can form f3-APP:HsLON complexes, can be used in diagnostics.

WO 00/02911 PCT/US99/15592 -20 Said molecules may be utilized in assays (e.g., immunoassays) to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders characterized by aberrant levels of f3-APP:HsLON complex, or monitor the treatment thereof. An "aberrant level" means an increased or decreased level in a sample relative to that present in an analogous sample from an unaffected part of the body, or from a 5 subject not having the disorder. The aforementioned immunoassay may be performed by a methodology comprising contacting a sample derived from a patient with an anti-p-APP, anti-HsLON, and/or anti-3-APP:HsLON complex antibody under conditions such that immunospecific-binding may occur, and subsequently detecting or measuring the amount of any immunospecific-binding by the antibody. In a specific embodiment, an antibody specific for p-APP, HsLON, and/or a p-APP:HsLON complex may 10 be used to analyze a tissue or serum sample from a patient for the presence of uncomplexed or complexed f3-APP:HsLON; wherein an aberrant level of f3-APP, HsLON, and/or p-APP:HsLON complex is indicative of a diseased condition. The immunoassays that may be utilized include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western Blots, radioimmunoassays (RIA), enzyme linked immunosorbent assay (ELISA), "sandwich" immunoassays, 15 immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein-A immunoassays, etc. The nucleic acid species of the present invention encoding the associated protein components of f3-APP:HsLON complex, and related nucleotide sequences and subsequences, may also be used in 20 hybridization assays. P-APP and HsLON nucleotide sequences, or subsequences thereof comprising at least 6 nucleotides, may be used as hybridization probes. Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant levels of the mRNAs encoding the components of a f-APP:HsLON complex, as described supra. In specific embodiments of the present invention, diseases and disorders involving or characterized by aberrant 25 levels of p-APP:HsLON complex or a predisposition to develop such disorders may be diagnosed by detecting aberrant levels of p-APP:HsLON complex, or non-complexed p-APP and/or HsLON proteins or nucleic acids for functional activity. This aforementioned functional activity may include, but is not restricted to, (i) binding to an interacting partner (e.g., p-APP, HsLON) or (ii) detecting mutations in p-APP and/or a HsLON RNA, DNA or protein (e.g., translocations, truncations, changes in nucleotide or 30 amino acid sequence relative to wild-type f3-APP and/or the HsLON) that can cause altered expression or activity of a p-APP, a HsLON or a P-APP:HsLON complex. Methodologies that are well-known within the art (e.g., immunoassays, nucleic acid hybridization assays, biological activity assays, and the like) may be used to determine whether one or more particular p-APP:HsLON complexes are present at either increased or decreased levels, or are WO 00/02911 PCT/US99/15592 -21 absent, within samples derived from patients suffering from a particular disease or disorder, or possessing a predisposition to develop such a disease or disorder, as compared to the levels in samples from subjects not having such disease or disorder or predisposition thereto. Additionally, these assays may be utilized to determine whether the ratio of p-APP:HsLON complex to the non-complexed 5 components (i.e. f-APP and/or HsLON) in the complex of interest is increased or decreased in samples from patients suffering from a particular disease or disorder or having a predisposition to develop such a disease or disorder as compared to the ratio in samples from subjects not having such a disease or disorder or predisposition thereto. Accordingly, in specific embodiments of the present invention, diseases and disorders that 10 involve altered levels of one or more p-APP:HsLON complex may be diagnosed, or their suspected presence may be screened for, or a predisposition to develop such diseases and disorders may be detected, by quantitatively ascertaining altered levels of: (i) the one or more p-APP:HsLON complex; (ii) the mRNA encoding both protein members of said complex; (iii) the complex functional activity or (iv) mutations in P-APP or the HsLON (e.g., translocations in nucleic acids, truncations in the gene or 15 protein, changes in nucleotide or amino acid sequence relative to wild-type fp-APP or the HsLON) that enhance/inhibit or stabilize/destabilize p-APP:HsLON complex formation. In the practice of the present invention, the use of detection techniques, especially those involving antibodies directed against p-APP:HsLON complex, provide methods for the detection of specific cells that express the uncomplexed or complexed protein of interest, e.g., p-APP and/or HsLON. 20 Using such assays, specific cell types may be quantitatively characterized in which one or more particular components of a p-APP:HsLON complex are expressed, and the presence of the uncomplexed or complexed protein may be correlated with cell viability by techniques well-known within the art (e.g., fluorescence-activated cell sorting). Also embodied herein are methodologies directed to the detection of a p-APP:HsLON complex within in vitro cell culture models that express a particular p-APP:HsLON 25 complex, or derivatives thereof, for the purpose of characterizing and/or isolating fp-APP:HsLON complex. These detection techniques include, but are not limited to, cell-sorting of prokaryotes (see e.g., Davey & Kell, 1996. Microbiol. Rev. 60: 641-696); primary cultures and tissue specimens from eukaryotes, including mammalian species such as human (see e.g., Steele, et al., 1996. Clin. Obstet. Gynecol. 39: 801-813) and continuous cell cultures (see e.g., Orfao & Ruiz-Arguelles, 1996. Clin. 30 Biochem. 29: 5-9. The present invention additionally provides kits for diagnostic use that are comprised of one or more containers containing an anti-f3-APP, anti-HsLON, and/or anti- f3-APP:HsLON complex antibody and, optionally, a labeled binding partner to said antibody. The label incorporated into the anti- P-APP:HsLON complex antibody may include, but is not limited to, a chemiluminescent, WO 00/02911 PCTIUS99/15592 -22 enzymatic, fluorescent, colorimetric or radioactive moiety. In another specific embodiment, kits for diagnostic use that are comprised of one or more containers containing modified or unmodified nucleic acids that encode, or alternatively, that are the complement to, [p-APP, HsLON, and/or p-APP:HsLON complex and, optionally, a labeled binding partner to said nucleic acids, are also provided. In an 5 alternative specific embodiment, the kit may comprise, in one or more containers, a pair of oligonucleotide primers (e.g., each 6-30 nucleotides in length) that are capable of acting as amplification primers for polymerase chain reaction (PCR; see e.g., Innis, et al., 1990. PCR PROTOCOLS, Academic Press, Inc., San Diego, CA), ligase chain reaction, cyclic probe reaction, and the like, or other methods known within the art. The kit may, optionally, further comprise a predetermined amount of a purified 10 p-APP, HsLON or P-APP:HsLON complex, or nucleic acids thereof, for use as a diagnostic, standard, or control in the aforementioned assays. (4) Therapeutic uses of [-APP and HsLON proteins and [p-APP:HsLON complexes The present invention provides a method for treatment or prevention of various diseases and disorders by administration of a biologically-active therapeutic compound (hereinafter "Therapeutic"). 15 Such "Therapeutics" include but are not limited to: (i) p-APP, HsLON, and p-APP:HsLON complex, and derivative, fragments, analogs and homologs thereof; (ii) antibodies directed against the aforementioned proteins and protein complex thereof; (iii) nucleic acids encoding p-APP and/or HsLON, and derivatives, fragments, analogs and homologs thereof; (iv) antisense nucleic acids to sequences encoding [-APP and HsLON proteins, and (v) [3-APP:HsLON complex and modulators 20 thereof ( i.e., inhibitors, agonists and antagonists). As previously discussed, p-APP and its binding partner HsLON, are implicated significantly in disorders including, but not limited to, neurodegenerative disorders such as Alzheimer's Disease, dementia of trisomy 21, Parkinson's disease, amyotrophic lateral sclerosis (ALS); cardiomyopathy; some forms of diabetes; hearing loss; and male infertility; as well as a number of less common syndromes and 25 disorders associated with mitochondrial DNA mutations. A wide range of cell diseases is treated or prevented by administration of a Therapeutic that modulates, i.e., antagonizes or promotes, [-APP:HsLON complex activity or formation. Diseases or disorders associated with aberrant levels of a [p-APP:HsLON complex or levels of 30 activity or aberrant levels of p-APP may be treated by administration of a Therapeutic that modulates [-APP:HsLON complex formation or activity. In a specific embodiment, the activity or levels of [-APP are modulated by administration of HsLON. In another specific embodiment, the activity or levels of HsLON are modulated by administration of [-APP.

WO 00/02911 PCT/US99/15592 -23 Disorders with Increased f-APP and p-APP:HsLON Complex Levels Diseases and disorders that are characterized by increased (relative to a subject not suffering from said disease or disorder) p-APP:HsLON levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) p-APP:HsLON complex formation or activity. 5 Therapeutics that antagonize p-APP:HsLON complex formation or activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, p-APP or HsLON, or analogs, derivatives, fragments or homologs thereof; (ii) anti-3-APP, anti-HsLON, and/or anti-f-APP:HsLON complex antibodies; (iii) nucleic acids encoding p-APP or HsLON; (iv) concurrent administration of a p-APP and a HsLON antisense nucleic acid and 1-APP and/or 10 HsLON nucleic acids that are "dysfunctional" (i.e., due to a heterologous [non-p-APP and/or non-HsLON] insertion within the coding sequences of 13-APP and HsLON coding sequences) are utilized to "knockout" endogenous p-APP and/or HsLON function by homologous recombination (see e.g., Capecchi, 1989. Science 244: 1288-1292). In an additional embodiment of the present invention, mutants or derivatives of a first HsLON that possess greater affinity for 1-APP than the wild-type first 15 HsLON may be administered to compete with a second HsLON for binding to 1-APP, thereby reducing the levels of complex between 1-APP and the second HsLON. Increased levels of p-APP:HsLON complex can be readily detected by quantifying protein and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or protein levels, structure and/or activity of the expressed p-APP:HsLON complex (or 1-APP and 20 HsLON mRNAs). Methods that are well-known within the art include, but are not limited to, immunoassays to detect p-APP:HsLON complex (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, and the like) and/or hybridization assays to detect concurrent expression of p-APP and HsLON mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like). 25 Reduction of p-APP and p-APP:HsLON Complex Expression A specific embodiment of the present invention discloses methods for the reduction of p-APP:HsLON complex expression (i.e., the expression of the two protein components of the complex and/or formation of the complex) by targeting mRNAs that express the protein moieties. RNA Therapeutics are differentiated into three classes: (i) antisense species; (ii) ribozymes or (iii) RNA 30 aptamers. See e.g., Good, et al., 1997. Gene Therapy 4: 45-54. Antisense oligonucleotides have been the most widely utilized and are discussed infra. Ribozyme therapy involves the administration (i.e., induced expression) of small RNA molecules with enzymatic ability to cleave, bind, or otherwise inactivate specific RNAs, thus reducing or eliminating the expression of particular proteins. See e.g., WO 00/02911 PCT/US99/15592 -24 Grassi & Marini, 1996. Ann. Med. 28: 499-5 10. At present, the design of "hairpin" and/or "hammerhead" RNA ribozymes are necessary to specifically-target a particular mRNA (e.g., fp-APP mRNA). RNA aptamers are specific RNA ligands for proteins, such as for Tat and Rev RNA (see e.g., Good, et al., 1997. Gene Therapy 4: 45-54) which can specifically inhibit their translation. 5 In a preferred embodiment of the present invention, the activity or level of p-APP may be reduced by administration of HsLON, a nucleic acid that encodes HsLON or an antibody (or a derivative or fragment of the antibody possessing the binding domain thereof) that immunospecifically-binds to HsLON. Similarly, the levels or activity of HsLON may be reduced by administration of p-APP, a nucleic acid encoding 3-APP or an antibody (or a derivative or fragment of the antibody possessing the 10 binding domain thereof) that immunospecifically-binds p-APP. In another embodiment of the present invention, diseases or disorders that are associated with increased levels of p-APP or HsLON, may be treated or prevented by administration of a Therapeutic that increases p-APP:HsLON complex formation, if said complex formation acts to reduce or inactivate 3-APP or the particular HsLON via 3-APP:HsLON complex formation. Such diseases or disorders may be treated or prevented by: (i) the 15 administration of one member of P-APP:HsLON complex, including mutants of one or both of the proteins that possess increased affinity for the other member of fp-APP:HsLON complex (so as to cause increased complex formation) or (ii) the administration of antibodies or other molecules that serve to stabilize p-APP:HsLON complex, or the like. (5) Determination of the Biological Effect of the Therapeutic 20 In preferred embodiments of the present invention, suitable in vitro or in vivo assays are utilized to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue. In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect 25 upon said cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects. Neurodegenerative disorders 30 1-APP and its binding partner HsLON have been implicated in neurodegenerative diseases. Accordingly, Therapeutics of the invention, particularly, but not limited to, those that modulate (or WO 00/02911 PCT/US99/15592 -25 supply) p-APP:HsLON complex activity, may be effective in treating or preventing neurodegenerative disease. Therapeutics of the present invention that modulate p-APP:HsLON complex activity involved in neurodegenerative disorders can be assayed by any method known in the art for efficacy in treating or preventing such neurodegenerative diseases and disorders. Such assays include in vitro assays for 5 regulated cell maturation or inhibition of apoptosis or in vivo assays using animal models of neurodegenerative diseases or disorders, or any of the assays described infra. Potentially effective Therapeutics, for example but not by way of limitation, promote regulated cell maturation and prevent cell apoptosis in culture, or reduce neurodegeneration in animal models in comparison to controls. Once a neurodegenerative disease or disorder has been shown to be amenable to treatment by 10 modulation of 13-APP:HsLON complex activity, that neurodegenerative disease or disorder can be treated or prevented by administration of a Therapeutic that modulates p3-APP:HsLON complex formation or activity, including supplying a p-APP:HsLON complex or an uncomplexed binding partner, e.g., P-APP and/or HsLON. Such diseases include all degenerative disorders involved with aging, especially osteoarthritis and neurodegenerative disorders. 15 Hypertrophic cardiomyopathy HsLON has been linked to several disorders and syndromes that share the common feature of hypertrophic cardiomyopathy. Accordingly, Therapeutics of the invention, particularly those that modulate (or supply) P-APP:HsLON complex activity or formation may be effective in treating or preventing hypertrophic cardiomyopathy and associated diseases or disorders. Therapeutics of the 20 invention (particularly Therapeutics that modulate the levels or activity of a p-APP:HsLON complex) can be assayed by any method known in the art, including those described infra, for efficacy in treating or preventing such diseases and disorders. Accordingly, once an hypertrophic cardiomyopathy-associated disease or disorder has been shown to be amenable to treatment by modulation of p-APP:HsLON complex activity or formation, that 25 disease or disorder can be treated or prevented by administration of a Therapeutic that modulates p-APP:HsLON complex activity or formation including supplying a f-APP:HsLON complex, or individual uncomplexed p-APP and/or HsLON proteins. Diabetes HsLON has been implicated in the development of maternally-inherited diabetes. Accordingly, 30 Therapeutics of the invention, particularly, but not limited to, those that modulate (or alter or supply) p-APP:HsLON complex activity, may be effective in treating or preventing neurodegenerative disease.

WO 00/02911 PCTIUS99/15592 -26 Therapeutics of the present invention that modulate f3-APP:HsLON complex activity involved in diabetes can be assayed by any method known in the art for efficacy in treating or preventing such diseases and disorders. Such assays include in vitro assays or in vivo assays using animal models of diabetes, or any of the assays described infra. Potentially effective Therapeutics, for example but not by 5 way of limitation, reduce diabetes in animal models in comparison to controls. Once a diabetes has been shown to be amenable to treatment by modulation of 3-APP:HsLON complex activity, that disease or disorder can be treated or prevented by administration of a Therapeutic that modulates p-APP:HsLON complex formation or activity, including supplying a p-APP:HsLON complex or an uncomplexed binding partner, e.g., f3-APP and/or HsLON. 10 Hearing Loss HsLON has been implicated in both sensorineural hearing loss and maternally-inherited deafness. Accordingly, Therapeutics of the invention, particularly but not limited to those that modulate (or supply) P-APP:HsLON complex activity, may be effective in treating or preventing sensorineural hearing loss or maternally-inherited deafness. Therapeutics of the present invention that modulate 15 p-APP:HsLON complex activity involved in sensorineural hearing loss or maternally-inherited deafness can be assayed by any method known in the art for efficacy in treating or preventing such diseases and disorders. Such assays include in vitro assays or in vivo assays using animal models of sensorineural hearing loss or maternally-inherited deafness, or any of the assays described infra. Potentially effective Therapeutics, for example but not by way of limitation, reduce sensorineural hearing loss or 20 maternally-inherited deafness in animal models in comparison to controls. Once a sensorineural hearing loss or maternally-inherited deafness has been shown to be amenable to treatment by modulation of p-APP:HsLON complex activity, that disease or disorder can be treated or prevented by administration of a Therapeutic that modulates p-APP:HsLON complex formation or activity, including supplying a 3-APP:HsLON complex or an uncomplexed binding 25 partner, e.g., p-APP and/or HsLON. Male Infertility HsLON has been implicated in the development of male infertility. Accordingly, Therapeutics of the invention, particularly but not limited to those that modulate (or supply) p-APP:HsLON complex activity, may be effective in treating or preventing male infertility. Therapeutics of the present invention 30 that modulate p-APP:HsLON complex activity involved in male infertility can be assayed by any method known in the art for efficacy in treating or preventing such diseases and disorders. Such assays WO 00/02911 PCT/US99/15592 -27 include in vitro assays or in vivo assays using animal models of male infertility, or any of the assays described infra. Potentially effective Therapeutics, for example but not by way of limitation, reduce male infertility in animal models in comparison to controls. Once a male infertility has been shown to be amenable to treatment by modulation of 5 1-APP:HsLON complex activity, that disease or disorder can be treated or prevented by administration of a Therapeutic that modulates f-APP:HsLON complex formation or activity, including supplying a [p-APP:HsLON complex or an uncomplexed binding partner, e.g., [-APP and/or HsLON. Diseases associated with mitochondrial DNA mutations HsLON has been implicated in a number of diseases or disorders associated with mitochondrial 10 DNA mutations. Accordingly, Therapeutics of the invention, particularly but not limited to those that modulate (or supply) p-APP:HsLON complex activity, may be effective in treating or preventing diseases or disorders associated with mitochondrial DNA mutations. Therapeutics of the present invention that modulate -APP:HsLON complex activity involved in diseases or disorders associated with mitochondrial DNA mutations can be assayed by any method known in the art for efficacy in 15 treating or preventing such diseases and disorders. Such assays include in vitro assays or in vivo assays using animal models of diseases or disorders associated with mitochondrial DNA mutations, or any of the assays described infra. Potentially effective Therapeutics, for example but not by way of limitation, reduce diseases or disorders associated with mitochondrial DNA mutations in animal models in comparison to controls. 20 Once diseases or disorders associated with mitochondrial DNA mutations have been shown to be amenable to treatment by modulation of p-APP:HsLON complex activity, that disease or disorder can be treated or prevented by administration of a Therapeutic that modulates fp-APP:HsLON complex formation or activity, including supplying a p-APP:HsLON complex or an uncomplexed binding partner, e.g., [p-APP and/or HsLON. 25 (6) Gene Therapy In a specific embodiment of the present invention, nucleic acids comprising a sequence that encodes [-APP and/or HsLON, or functional derivatives thereof, are administered to modulate j-APP:HsLON complex function, by way of gene therapy. In more specific embodiments, a nucleic acid or nucleic acids encoding both [-APP and HsLON, or functional derivatives thereof, are administered by 30 way of gene therapy. Gene therapy refers to therapy that is performed by the administration of a specific nucleic acid to a subject. In this embodiment of the present invention, the nucleic acid produces its WO 00/02911 PCT/US99/15592 -28 encoded protein(s), which then serve to exert a therapeutic effect by modulating P-APP:HsLON complex function. Any of the methodologies relating to gene therapy available within the art may be used in the practice of the present invention. See e.g., Goldspiel, et al., 1993. Clin. Pharm. 12: 488-505. In a preferred embodiment, the Therapeutic comprises a p-APP and/or HsLON nucleic acid that 5 is part of an expression vector expressing both of the aforementioned proteins, or fragments or chimeric proteins thereof, within a suitable host. In a specific embodiment, such a nucleic acid possesses a promoter that is operably-linked to p-APP and HsLON coding region(s), or, less preferably, two separate promoters linked to separate p-APP and HsLON coding regions. Said promoter may be inducible or constitutive, and, optionally, tissue-specific. In another specific embodiment, a nucleic acid molecule is 10 used in which p-APP and HsLON coding sequences (and any other desired sequences) are flanked by regions that promote homologous recombination at a desired site within the genome, thus providing for intra-chromosomal expression of [-APP and HsLON nucleic acids. See e.g., Koller & Smithies, 1989. Proc. NatL. Acad. Sci. USA 86: 8932-8935. Delivery of the Therapeutic nucleic acid into a patient may be either direct (i.e., the patient is 15 directly exposed to the nucleic acid or nucleic acid-containing vector) or indirect (i.e., cells are first transformed with the nucleic acid in vitro, then transplanted into the patient). These two approaches are known, respectively, as in vivo or ex vivo gene therapy. In a specific embodiment of the present invention, a nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product. This may be accomplished by any of numerous methods known in the art including, but not 20 limited to, constructing said nucleic acid as part of an appropriate nucleic acid expression vector and administering the same in a manner such that it becomes intracellular (e.g., by infection using a defective or attenuated retroviral or other viral vector; see U.S. Patent No. 4,980,286); directly injecting naked DNA; using microparticle bombardment (e.g., a "Gene Gun*; Biolistic, DuPont); coating said nucleic acids with lipids; using associated cell-surface receptors/transfecting agents; encapsulating in 25 liposomes, microparticles, or microcapsules; administering it in linkage to a peptide that is known to enter the nucleus; or by administering it in linkage to a ligand predisposed to receptor-mediated endocytosis (see e.g., Wu & Wu, 1987. J. Biol. Chem. 262: 4429-4432), which can be used to "target" cell types that specifically express the receptors of interest, etc. In another specific embodiment of the present invention, a nucleic acid-ligand complex may be 30 produced in which the ligand comprises a fusogenic viral peptide designed so as to disrupt endosomes, thus allowing the nucleic acid to avoid subsequent lysosomal degradation. In yet another specific embodiment, the nucleic acid may be targeted in vivo for cell-specific endocytosis and expression, by targeting a specific receptor. See e.g., PCT Publications WO 92/06180; W093/14188 and WO 93/20221. Alternatively, the nucleic acid may be introduced intracellularly and incorporated within WO 00/02911 PCT/US99/15592 -29 a host cell genome for expression by homologous recombination. See e.g., Zijlstra, et al., 1989. Nature 342: 435-438. In yet another specific embodiment, a viral vector that contains p-APP and/or HsLON nucleic acids is utilized. For example, retroviral vectors may be employed (see e.g., Miller, et al., 1993. Meth. 5 Enzymol. 217: 581-599) that have been modified to delete those retroviral-specific sequences that are not required for packaging of the viral genome, with its subsequent integration into host cell DNA. p-APP and/or HsLON (preferably both) nucleic acids may be cloned into a vector that facilitates delivery of the genes into a patient. See e.g., Boesen, et al., 1994. Biotherapy 6: 291-302; Kiem, et al., 1994. Blood 83: 1467-1473. Additionally, adenovirus may be used as an especially efficacious "vehicle" for the delivery 10 of genes to the respiratory epithelia. Other targets for adenovirus-based delivery systems are liver, central nervous system, endothelial cells, and muscle. Adenoviruses also possess advantageous abilities to infect non-dividing cells. For a review see e.g., Kozarsky & Wilson, 1993. Curr. Opin. Gen. Develop. 3: 499-503. Adenovirus-associated virus (AAV) has also been proposed for use in gene therapy. See e.g., Walsh, et al., 1993. Proc. Soc. Exp. Biol. Med. 204: 289-300. 15 An additional approach to gene therapy in the practice of the present invention involves transferring a gene into cells in in vitro tissue culture by such methods as electroporation, lipofection, calcium phosphate-mediated transfection, viral infection, or the like. Generally, the methodology of transfer includes the concomitant transfer of a selectable marker to the cells. The cells are then placed under selection pressure (e.g., antibiotic resistance) so as to facilitate the isolation of those cells that 20 have taken up, and are expressing, the transferred gene. Those cells are then delivered to a patient. In a specific embodiment, prior to the in vivo administration of the resulting recombinant cell, the nucleic acid is introduced into a cell by any method known within the art including, but not limited to: transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences of interest, cell fusion, chromosome-mediated gene transfer, 25 microcell-mediated gene transfer, spheroplast fusion, and similar methodologies that ensure that the necessary developmental and physiological functions of the recipient cells are not disrupted by the transfer. See e.g., Loeffler & Behr, 1993. Meth. Enzymol. 217: 599-618. The chosen technique should provide for the stable transfer of the nucleic acid to the cell, such that the nucleic acid is expressible by the cell. Preferably, said transferred nucleic acid is heritable and expressible by the cell progeny. 30 In preferred embodiments of the present invention, the resulting recombinant cells may be delivered to a patient by various methods known within the art including, but not limited to, injection of epithelial cells (e.g., subcutaneously), application of recombinant skin cells as a skin graft onto the patient, and intravenous injection of recombinant blood cells (e.g., hematopoietic stem or progenitor WO 00/02911 PCTIUS99/15592 -30 cells). The total amount of cells that are envisioned for use depend upon the desired effect, patient state, and the like, and may be determined by one skilled within the art. Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and may be xenogeneic, heterogeneic, syngeneic, or autogeneic. Cell types 5 include, but are not limited to, differentiated cells such as epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes and blood cells, or various stem or progenitor cells, in particular embryonic heart muscle cells, liver stem cells (International Patent Publication WO 94/08598), neural stem cells (Stemple and Anderson, 1992, Cell 71: 973-985), hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, 10 and the like. In a preferred embodiment, the cells utilized for gene therapy are autologous to the patient. In a specific embodiment in which recombinant cells are used in gene therapy, stem or progenitor cells that can be isolated and maintained in vitro may be utilized. Such stem cells include, but are not limited to, hematopoietic stem cells (HSC), stem cells of epithelial tissues, and neural stem cells (see e.g., Stemple & Anderson, 1992. Cell 71: 973-985). With respect to HSCs, any technique that 15 provides for the isolation, propagation, and maintenance in vitro of HSC may be used in this specific embodiment of the invention. As previously discussed, the HSCs utilized for gene therapy may, preferably, be autologous to the patient. When used, non-autologous HSCs are, preferably, utilized in conjunction with a method of suppressing transplantation immune reactions of the future host/patient. See e.g., Kodo, et al., 1984. J. Clin. Invest. 73: 1377-1384. In another preferred embodiment of the 20 present invention, HSCs may be highly enriched (or produced in a substantially-pure form), by any techniques known within the art, prior to administration to the patient. See e.g., Witlock & Witte, 1982. Proc. Natl. Acad. Sci. USA 79: 3608-3612. (7) Utilization of Anti-Sense Oligonucleotides In a specific embodiment of the present invention, p-APP, HsLON, and/or p-APP:HsLON 25 complex formation and function may be inhibited by the use of anti-sense nucleic acids for fp-APP or HsLON, or most preferably, fp-APP and HsLON. In addition, the present invention discloses the therapeutic or prophylactic use of nucleic acids (of at least six nucleotides in length) that are anti-sense to a genomic sequence (gene) or cDNA encoding j-APP and/or HsLON, or portions thereof. Such anti-sense nucleic acids have utility as Therapeutics that inhibit p-APP, HsLON, and/or p-APP:HsLON 30 complex formation or activity, and may be utilized in a therapeutic or prophylactic manner. Another specific embodiment of the present invention discloses methodologies for inhibition of expression of p-APP and HsLON nucleic acid sequences within a prokaryotic or eukaryotic cell, such as WO 00/02911 PCT/US99/15592 -31 providing a cell with an therapeutically-effective amount of an anti-sense nucleic acid of -APP and/or HsLON, or derivatives thereof. The anti-sense nucleic acids of the present invention may be oligonucleotides that may either be directly administered to a cell or that may be produced in vivo by transcription of the exogenous, 5 introduced sequences. In addition, the anti-sense nucleic acid may be complementary to either a coding (i.e., exonic) and/or non-coding (i.e., intronic) region of p-APP or HsLON mRNAs. p-APP and HsLON anti-sense nucleic acids are, at least, six nucleotides in length and are, preferably, oligonucleotides ranging from 6-200 nucleotides in length. In specific embodiments, the anti-sense oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides. The 10 anti-sense oligonucleotides may be DNA or RNA (or chimeric mixtures, derivatives or modified versions thereof), may be either single-stranded or double-stranded and may be modified at a base, sugar or phosphate backbone moiety. In addition, said anti-sense oligonucleotide may include other associated functional groups, such as peptides, moieties that facilitate the transport of the oligonucleotide across the cell membrane, 15 hybridization-triggered cross-linking agents, hybridization-triggered cleavage-agents, and the like. See e.g., Letsinger, et al., 1989. Proc. Nat?. Acad. Sci. US.A. 86: 6553-6556; PCT Publication No. WO 88/09810. In a specific embodiment, p-APP and HsLON antisense oligonucleotides comprise catalytic RNAs or ribozymes. See, e.g., Sarver, et al., 1990. Science 247: 1222-1225. The anti-sense oligonucleotides of the present invention may be synthesized by standard 20 methodologies known within the art including, but not limited to: (i) automated phosphorothioate-mediated oligonucleotide synthesis (see e.g., Stein, et al., 1988. Nuc. Acids Res. 16: 3209) or (ii) methylphosphonate oligonucleotides prepared by use of controlled pore glass polymer supports (see e.g., Sarin, et al., 1988. Proc. Nat?. Acad. Sci. US.A. 85: 7448-7451). In an alternative embodiment, p-APP and HsLON antisense nucleic acids are produced 25 intracellularly by transcription of an exogenous sequence. For example, a vector comprising a promoter functionally linked to the reverse complement of a desired gene, and the like, may be produced that (upon being taken up by the cell) is transcribed in vivo, thus producing an antisense nucleic acid (RNA) species. The aforementioned vector may either remain episomal or become chromosomally-integrated, so long as it can be transcribed to produce the desired antisense RNA. An origin of the vectors utilized 30 may be derived from bacterial, viral, yeast or other sources known within the art that are utilized for replication and expression in mammalian cells. Expression of the sequences encoding 13-APP and HsLON antisense RNAs may be facilitated by any promoter known within the art to function in mammalian, preferably, human cells. Such promoters may be inducible or constitutive and include, but WO 00/02911 PCTIUS99/15592 -32 are not limited to: (i) the SV40 early promoter region; (ii) the promoter contained in the 3'-terminus long terminal repeat of Rous sarcoma virus (RSV); (iii) the Herpesvirus thymidine kinase promoter and (iv) the regulatory sequences of the metallothionein gene. p-APP and HsLON antisense nucleic acids may be utilized prophylactically or therapeutically in 5 the treatment or prevention of disorders of a cell type that expresses (or preferably over-expresses) fp-APP, HsLON, and/or p-APP:HsLON complex. Cell types that express or over-express f3-APP and HsLON RNA may be identified by various methods known within the art including, but not limited to, hybridization with [-APP and HsLON-specific nucleic acids (e.g., by Northern hybridization, dot blot hybridization, in situ hybridization) or by observing the ability of RNA from the specific cell type to be 10 translated in vitro into [-APP and/or HsLON by immunohistochemistry. In a preferred aspect, primary tissue from a patient may be assayed for p-APP and/or HsLON expression by, for example, immunocytochemistry or in situ hybridization, prior to actual treatment. Pharmaceutical compositions of the present invention, comprising an effective amount of a p-APP and HsLON antisense nucleic acid contained within a pharmaceutically-acceptable carrier, may 15 be administered to a patient having a disease or disorder of a type that involves modified expression of f3-APP:HsLON complex, or of RNA or protein of the individual components of said complex. The amount of p-APP and/or HsLON antisense nucleic acid that is effective in the treatment of a particular disorder or condition will be dependant upon the nature of the disorder or condition, and may be determined by standard clinical techniques. Where possible, it is desirable to determine the antisense 20 cytotoxicity in in vitro systems and in useful animal model prior to testing and use in humans. In a specific embodiment, pharmaceutical compositions comprising [3-APP and HsLON antisense nucleic acids may be administered via liposomes, microparticles, or microcapsules or the like. See, e.g., supra, and Leonetti, et al., 1990. Proc. NatI. Acad. Sci. US.A. 87: 2448-2451. (8) f3-APP:HsLON Complex Assays 25 The functional activity of 3-APP:HsLON complex (and derivatives, fragments, analogs and homologs thereof) may be assayed by a number of methods known in the art. For example, putative modulators (e.g., inhibitors, agonists and antagonists) of p-APP:p-APP complex activity (e.g., anti-p-APP:HsLON complex antibodies, as well as P-APP or HsLON antisense nucleic acids) may be assayed for their ability to modulate P-APP:HsLON complex formation and/or activity.

WO 00/02911 PCT/US99/15592 -33 Immunoassays In a specific embodiment, immunoassay-based methodologies are provided wherein one is assaying for: (i) the ability to bind to, or compete with, wild-type p-APP:HsLON complex or HsLON, or (ii) the ability to bind to an anti-p3-APP:HsLON complex antibody. These immunoassays include, but 5 are not limited to, competitive and non-competitive assay systems utilizing techniques such as radioimmunoassays, enzyme linked immunosorbent assay (ELISA), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (e.g., using colloidal gold, enzyme or radioisotope labels), complement fixation assays, Western blots, Northwestern blots, precipitation reactions, agglutination assays (e.g., gel agglutination 10 assays, hemagglutination assays), immunofluorescence assays, protein-A assays and immunoelectrophoresis assays, and the like. In one specific embodiment, antibody binding is detected directly by assaying for a label on a primary antibody. In another specific embodiment, binding of the primary antibody is ascertained by detection of a secondary antibody (or reagent) that is specific for the primary antibody. In a further embodiment, the secondary antibody is labeled. 15 Gene Expression Assays Expression of p-APP or HsLON genes (from both endogenous genes and from incorporated recombinant DNA) may be detected using techniques known within the art including, but not limited to, Southern hybridization, Northern hybridization, restriction endonuclease mapping, DNA sequence analysis, and polymerase chain reaction amplification (PCR) followed by Southern hybridization or 20 RNase protection (see e.g., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY 1997, John Wiley and Sons, New York, NY) with probes specific for 13-APP and HsLON genes in various cell types. In one specific embodiment of the present invention, Southern hybridization may be used to detect genetic linkage of p-APP and/or HsLON gene mutations to physiological or pathological states. Numerous cell types, at various stages of development, may be characterized for their expression of 25 1-APP and HsLON (particularly the concomitant expression of 1-APP and HsLON within the same cells). The stringency of the hybridization conditions for Northern or Southern blot analysis may be manipulated to ensure detection of nucleic acids with the desired degree of relatedness to the specific probes used. See, e.g., supra. Modification of these aforementioned methods, as well as other methods well-known within the art, may be utilized in the practice of the present invention.

WO 00/02911 PCTIUS99/15592 -34 Binding Assays Derivatives, fragments, analogs and homologs of HsLON may be assayed for binding to p-APP by any method known within the art including, but not limited to: (i) the modified yeast two hybrid assay system; (ii) immunoprecipitation with an antibody that binds to P-APP within a complex, followed 5 by analysis by size fractionation of the immunoprecipitated proteins (e.g., by denaturing or non-denaturing polyacrylamide gel electrophoresis); (iii) Western analysis; (v) non-denaturing gel electrophoresis, and the like. Alternatively, the aforementioned techniques may be modified to allow for the reverse analysis, whereby 13-APP components bind to HsLON. Assays for Biological Activity 10 A specific embodiment of the present invention provides a methodology for screening a derivative, fragment, analog or homolog of fp-APP for biological activity, which is comprised of contacting said derivative, fragment, analog or homolog of f-APP with HsLON and detecting complex formation between said derivative, fragment, analog or homolog of 3-APP and HsLON; wherein the detection of the formation of said complex indicates that said 3-APP derivative, fragment, analog or 15 homolog, possesses biological (e.g., binding) activity. Similarly, an additional embodiment discloses a methodology for the screening a derivative, fragment, analog or homolog of HsLON for biological activity comprising contacting said derivative, fragment, analog or homolog of said protein with p-APP; and detecting complex formation between said derivative, fragment, analog or homolog of HsLON and fp-APP; wherein detecting the formation of said complex indicates that said HsLON derivative, 20 fragment, analog, or homolog possesses biological activity. Related Treatment Assays Neurodegeneration Similarly, once a neurodegeneration disease or disorder has been shown to be amenable to treatment by modulation of p-APP, HsLON, and/or p-APP:HsLON complex activity or formation, that 25 disease or disorder can be treated or prevented by administration of a Therapeutic that modulates r-APP:HsLON complex activity or formation, including supplying f3-APP, HsLON, and/or -APP:HsLON complex. In a specific embodiment, f-APP, HsLON, and/or fp-APP:HsLON complex is administered to treat or prevent a neurodegenerative disease or disorder. fp-APP has been implicated in the development and involution of all organs, including the central nervous system. Casaccia-Bonnefil 30 et al., 1997, Genes and Dev. 11: 2335-2346. Accordingly, a p-APP:HsLON complex or derivative, homolog, analog or fragment thereof, nucleic acid molecules encoding p-APP or HsLON, WO 00/02911 PCT/US99/15592 -35 anti-jP-APP:HsLON complex antibodies, and other modulators of p-APP, HsLON, and/or p-APP:HsLON complex activity or formation can be tested for activity in treating or preventing neurodegenerative disease in in vitro and in vivo assays. In one embodiment, a Therapeutic of the invention can be assayed for activity in treating or 5 preventing neurodegenerative disease by contacting a cultured cell that exhibits an indicator of a neurodegenerative disease in vitro with the Therapeutic and comparing the level of said indicator in the cell so contacted with the Therapeutic, with said level of said indicator in a cell not so contacted, wherein a lower level in said contacted cell indicates that the Therapeutic has activity in treating or preventing neurodegenerative disease. Specific examples of such cultured models for neurodegenerative 10 disease include, but are not limited to, cultured rat endothelial cells from affected and nonaffected individuals (Maneiro et al., 1997, Methods Find. Exp. Clin. Pharmacol. 19: 5-12); P19 murine embryonal carcinoma cells (Hung et al., 1992, Proc. Natl. Acad. Sci. USA 89: 9439-9443); and dissociated cell cultures of cholinergic neurons from nucleus basalis of Meynert (Nakajima et al., 1985, Proc. Nati. Acad. Sci. USA 82: 6325-6329). 15 In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing neurodegenerative disease by administering the Therapeutic to a test animal that is predisposed to develop symptoms of a neurodegenerative disease, and measuring the change in said symptoms after administration of said Therapeutic, wherein a reduction in the severity of the symptoms of the neurodegenerative disease, or the prevention of the symptoms of the neurodegenerative disease, 20 indicates that the Therapeutic has activity in treating or preventing said disease states. Such a test animal can be any one of a number of animal models known in the art for neurodegenerative disease. These models, including those for Alzheimer's Disease and mental retardation of trisomy 21, accurately mimic natural human neurodegenerative diseases. Farine, 1997, Toxicol. 119: 29-35. Examples of specific models include, but are not limited to, the partial trisomy 16 mouse (Holtzman et al., 1996, 25 Proc. Natl. Acad. Sci. USA 93: 13333-13338); bilateral nucleus basalis magnocellularis-lesioned rats (Popovic et al., 1996, Int. J. Neurosci. 86: 281-299); the aged rat (Muir, 1997, Pharmacol. Biochem. Behav. 56: 687-696); the PDAPP transgenic mouse model of Alzheimer's disease (Johnson-Wood et al., 1997, Proc. Natl. Acad. Sci. USA 94: 1550-1555); and experimental autoimmune dementia (Oron et al., 1997, J. Neural Transm. Suppl. 49: 77-84). 30 Cardiomyopathy In a specific embodiment of the present invention, a f-APP:HsLON complex is administered to treat or prevent a disease or disorder involving cardiomyopathy. HsLON has been linked to several disorders and syndromes that share the common feature of hypertrophic cardiomyopathy. Accordingly, WO 00/02911 PCTIUS99/15592 -36 a p-APP:HsLON complex or a derivative, homolog, analog or fragment thereof, nucleic acids encoding the 3-APP and HsLON proteins, anti- 3-APP:HsLON antibodies, and other modulators of p-APP:HsLON complex activity or formation, can be tested for activity in treating or preventing a disease or disorder involving cardiomyopathy in in vitro and in vivo assays. 5 In one embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing cardiomyopathy by contacting cultured cells, such as but not limited to, cultured cardiac myocytes from neonates (Wall et al., 1996, Eur. J. Pharmacol. 306:165-174) or adults (Hain and Schaper, 1996, Curr. Opin. Cardiol. 11:293-301), and cultured autoreactive T cells in autoimmune myocarditis (Perez-Leiros et al., 1997, Neuroimmunomodulation 4:91-97) that exhibit an indicator of 10 cardiomyopathy in vitro, with the Therapeutic, and comparing the level of said indicator in the cells contacted with the Therapeutic, with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the Therapeutic has activity in treating or preventing cardiomyopathy. In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or 15 preventing cardiomyopathy by administering the Therapeutic to a test animal exhibiting symptoms of cardiomyopathy; and measuring the change in said symptoms of cardiomyopathy after administration of said Therapeutic, wherein a reduction in the severity of the symptoms, or prevention of the symptoms, of cardiomyopathy indicates that the Therapeutic has activity in treating or preventing cardiomyopathy. Such a test animal can be any one of a number of animal models known in the art for cardiomyopathy. 20 These models include, but are not limited to, those of aryl-hydrocarbon receptor-deficient mice (Fernandez-Salguero et al., 1997, Vet. Pathol. 34: 605-614), experimental autoimmune myocarditis in mice (Perez-Leiros et al., 1997, Neuroimmunomodulation 4: 91-97), transgenic mice overexpressing tropomodulin (Sussman et al., 1998, J. Clin. Invest. 101: 51-61), guinea pigs immunized with adenine nucleotide transporter type I (Dorner et al., 1997, Mol. Cell. Biochem. 174: 261-269), MLP-deficient 25 mice (Arber et al., 1997, Cell 88: 393-403), and adenine nucleotide translocator type I - knockout mice (Graham et al., 1997, Nat. Genet. 16: 226-234). The relationship of cardiomyopathy in these models to heart disease in general is well reviewed by Christensen et al., 1997, Am. J Physiol. 272: H2513-H2524. Diabetes In yet another specific embodiment of the present invention, a 3-APP:HsLON complex is 30 administered to a subject to treat or prevent diabetes in the subject. HsLON has been implicated in the development of maternally-inherited diabetes. Accordingly, a p-APP:HsLON complex or a derivative, homolog, analog or fragment thereof, nucleic acids encoding the p-APP and HsLON proteins, anti-p-APP:HsLON antibodies, and other modulators of p-APP:HsLON complex activity or formation, WO 00/02911 -3 PCTIUS99/15592 -37 can be tested for activity in treating or preventing diabetes in in vitro and in vivo assays. In one embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing diabetes by contacting cultured cells that exhibit an indicator of diabetes in vitro with the Therapeutic, and comparing the level of said indicator in the cells contacted with the Therapeutic, with 5 said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the Therapeutic has activity in treating or preventing diabetes or its sequelae. Specific examples of such cultured models of diabetes include, but are not limited to, cultured rat endothelial cells from affected and nonaffected individuals (Bazan et al., 1997, Therapie 52: 447-451), antigen-specific lymphocytes cultured from TCR-HA transgenic mice (Sarukhan et al., 1998, EMBO J. 10 17: 71-80), the DAP.3Ag7 transfected mouse fibroblast cell line (Nabavieh et al., 1998, J. Autoimmun. 11: 63-71), and white blood cell isolates from affected and non-affected human individuals (Elhadd et al., 1997, QJ.M 90: 461-464). In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing diabetes by administering the Therapeutic to a test animal exhibiting symptoms of diabetes, 15 and measuring the change in said symptoms of diabetes after administration of said Therapeutic, wherein a reduction in the severity of the symptoms of, or prevention of, diabetes indicates that the Therapeutic has activity in treating or preventing diabetes. Such a test animal can be any one of a number of animal models known in the art for diabetes including, but not limited to, the non-obese diabetic mouse model of diabetes (Delovitch and Singh, 1997 Immunity 7: 727-738), TCR-HA 20 transgenic mice (Sarukhan et al., 1998, EMBO J. 17:71-80), IL-2-expressing transgenic mice (Elliot and Flavell, 1994, Int. Immunol. 6:1629-1637), and NOS2-expressing transgenic mice (Takamura et al., 1998, J. Biol. Chem. 273:2493-2496). Hearing Loss In another specific embodiment of the present invention, a 3-APP:HsLON complex is 25 administered to treat or prevent hearing loss. HsLON has been implicated in both sensorineural hearing loss and maternally-inherited deafness. Accordingly, a p-APP:HsLON complex or a derivative, homolog, analog or fragment thereof, nucleic acids encoding the p-APP and HsLON proteins, anti-f-APP:HsLON antibodies, and other modulators of p-APP:HsLON complex activity or formation, can be tested for activity in treating or preventing hearing loss in in vitro and in vivo assays. 30 In one embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing hearing loss by contacting cultured cells that exhibit an indicator of decreased function in vitro with the Therapeutic, and comparing the level of said indicator in the cells contacted with the WO 00/02911 PCTIUS99/15592 -38 Therapeutic, with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the Therapeutic has activity in treating or preventing hearing loss. Specific examples of such cultured models for hearing loss include, but are not limited to, cultured sensory epithelia from the mammalian inner ear (Holley and Lawlor, 1997, Audiol. Neurootol. 2:25-35), cultured 5 auditory cortical neurons (Gopal and Gross, 1996, Acta Otolaryngol (Stockh) 116:690-696), and cultured spiral ganglia neurons (Marzella et al., 1997, Neuroreport 8:1641-1644). In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing hearing loss by administering the Therapeutic to a test animal that is predisposed to develop hearing loss, and measuring the change in said hearing loss after administration of said Therapeutic, 10 wherein a reduction in the severity of the symptoms of, or prevention of, the hearing loss indicates that the Therapeutic has activity in treating or preventing hearing loss. Such a test animal can be any one of a number of animal models known in the art for hearing loss. These models include, but are not limited to, mouse (Steel and Brown, 1994, Trends Genet. 10:428-435) and human (Hughes, 1997, Audiol. Neurootol. 2:3-11) genetic models of hearing loss, aminoglycoside ototoxicity in cats (Leake et al., 15 1997, Hear. Res. 113:117-132), and congenital deafness in Dalmatians (Niparko and Finger, 1997, Otolaryngol. Head Neck Surg. 117:229-235). Male Infertility In yet another specific embodiment of the present invention, a p-APP:HsLON complex is administered to treat or prevent male infertility. HsLON has been implicated in the development of 20 male infertility. Accordingly, a fp-APP:HsLON complex or a derivative, homolog, analog or fragment thereof, nucleic acids encoding the p-APP and HsLON proteins, anti-p-APP:HsLON antibodies, and other modulators of P-APP:HsLON complex activity or formation, can be tested for activity in treating or preventing male infertility in in vitro and in vivo assays. In one embodiment, a Therapeutic of the invention can be assayed for activity in treating or 25 preventing male infertility by contacting cultured cells that exhibit an indicator of male infertility in vitro with the Therapeutic, and comparing the level of said indicator in the cells contacted with the Therapeutic, with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the Therapeutic has activity in treating or preventing male infertility. Specific examples of such cultured models for male infertility include, but are not limited to, 30 spermatogenic cell cultures from affected and unaffected individuals (Blanchard et al., 1991, Mol. Reprod. Dev. 30: 275-282), cultured Leydig cells and macrophages from rat testes (Dirami et al., 1991, J. Endocrinol. 130: 357-365), and cultured mammalian Sertoli cells (Syed et al., 1997, J. Androl. 18: 264-273).

WO 00/02911 PCT/US99/15592 -39 In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing male infertility by administering the Therapeutic to a test animal that is infertile, and measuring the change in said symptoms of the male infertility after administration of said Therapeutic, wherein a reduction in the severity of the symptoms of, or prevention of, the symptoms of male 5 infertility indicates that the Therapeutic has activity in treating or preventing male infertility. Such a test animal can be any one of a number of animal models known in the art for male infertility including, but not limited to, mice expressing t haplotypes (Olds-Clarke, 1997, Rev. Reprod. 2:157-164), the syngeneic neonatal testicular graft model (Johnson et al., 1997, Contracept. Fertil. Sex 25:549-555), Sertoli cell depleted rats (Orth et al., 1988, Endocrinology 122:787-794), the aging male brown-Norway rat (Wang 0 et al., 1993, Endocrinology 133:2733-2781), and hybrid sterile mice Forejt, 1996, Trends Genet. 12:412-417). The applicability that these animal models have to future human therapeutics is well described in the review by Lamb and Niederberger, 1994, Urol. Clin. North Am. 21:377-387. Diseases associates with mitochondrial DNA mutations In a specific embodiment of the present invention, a fp-APP:HsLON complex is administered to 15 treat or prevent a disease or disorder associated with mitochondrial DNA mutations. HsLON has been implicated in a number of diseases or disorders associated with mitochondrial DNA mutations. Further, through the link between neurodegeneration and mitochondrial dysfunction, 13-APP is also implicated in diseases of mitochondria. Accordingly, a p-APP:HsLON complex, nucleic acids encoding the p-APP and HsLON proteins, anti- p-APP:HsLON antibodies, and other modulators of f-APP:HsLON complex 20 activity or formation, or derivatives, fragments, analogs or homologs thereof, can be tested for activity in treating or preventing a disease or disorder associated with mitochondrial DNA mutations in in vitro and in vivo assays. In one embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing a disease or disorder associated with mitochondrial DNA mutation by contacting cultured :5 cells that exhibit an indicator of a disease or disorder associated with mitochondrial DNA mutations in vitro with the Therapeutic, and comparing the level of said indicator in the cells contacted with the Therapeutic, with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the Therapeutic has activity in treating or preventing diseases or disorders associated with mitochondrial DNA mutations. Specific examples of such cultured models for diseases 0 or disorders associated with mitochondrial DNA mutations include, but are not limited to, cultured myotubes from muscles of unaffected individuals and individuals with mitochondrial myopathies (Collombet et al., 1996, Mol. Gen. Genet. 253:182-188), cultured human skin fibroblasts unaffected humans and from humans with diseases associated with mtDNA deletions (van de Corput et al., 1997, J.

WO 00/02911 PCT/US99/15592 -40 Histochem. Cytochem. 45:55-61), and cultured cell lines harboring various mtDNA mutations (Spelbrink et al., 1997, Curr. Genet. 32:115-124). In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing a disease or disorder associated with mitochondrial DNA mutation by administering the 5 Therapeutic to a test animal having symptoms associated with mitochondrial DNA mutations, and measuring the change in said symptoms after administration of said Therapeutic, wherein a reduction in the severity of the symptoms of, or prevention of, the symptoms of the disease or disorder associated with mitochondrial DNA mutations, indicates that the Therapeutic has activity in treating or preventing a disease or disorder associated with mitochondrial DNA mutations. Such a test animal can be any one of 10 a number of animal models known in the art for diseases or disorders associated with mitochondrial DNA mutations. These models include, but are not limited to, liver, heart, and brain tissues from adult and senescent rats (Gadaleta et al., 1992, Mut. Res. 275:181-193), skeletal muscle tissue from adult and aging rhesus monkeys (Lee et al., 1993, J. Gerontol. 48:B201-B205), and primate xenomitochondrial cybrids (Kenyon and Moraes, 1997, Proc. Natl. Acad. Sci. USA 94:9131-9135. 15 Modulation of P-APP:HsLON Complex Activity The present invention provides methodologies relating to modulating the level or activity of a protein moiety that possesses the ability to participate in a p-APP:HsLON complex, via the administration of a binding partner of that protein (or derivative, fragment, analog or homolog thereof). p-APP (and derivatives, fragments, analogs and homologs thereof) may be assayed for its ability to 20 modulate the activity or levels of HsLON by contacting a cell, or administering to an animal expressing the HsLON gene, with p-APP protein, or, alternatively, with a nucleic acid encoding p-APP or an antibody that immunospecifically-binds p-APP, or derivative, fragment, analog, or homolog thereof that contains the antibody binding domain, and measuring a change in HsLON levels or activity, wherein said change in HsLON levels or activity indicates that said 3-APP possesses the ability to modulate 25 HsLON levels or activity. In another embodiment, HsLON (and derivatives, fragments, analogs and homologs thereof) may be assayed for their ability to modulate the activity or levels of p-APP in an analogous manner. Protein-Protein Interaction Assays The present invention discloses methodologies for assaying and screening derivatives, 30 fragments, analogs and homologs of HsLON for binding to p-APP. The derivatives, fragments, analogs and homologs of the HsLON that interact with p-APP may be identified by means of a yeast two hybrid assay system (see e.g., Fields & Song, 1989. Nature 340: 245-246) or; preferably, a modification and WO 00/02911 PCT/US99/15592 -41 improvement thereof, as described in U.S. Patent Applications Serial Nos. 08/663,824 (filed June 14, 1996) and 08/874,825 (filed June 13, 1997), to Nandabalan, et al., and that are incorporated by reference herein in their entireties. The identification of interacting proteins by the improved yeast two hybrid system is based upon 5 the detection of the expression of a reporter gene (hereinafter "Reporter Gene"), the transcription of which is dependent upon the reconstitution of a transcriptional regulator by the interaction of two proteins, each fused to one half of the transcriptional regulator. The bait f3-APP (or derivative, fragment, analog or homolog) and prey protein (proteins to be tested for ability to interact with the bait protein) are expressed as fusion proteins to a DNA-binding domain, and to a transcriptional regulatory domain, 10 respectively, or vice versa. In a specific embodiment of the present invention, the prey population may be one or more nucleic acids encoding mutants of HsLON (e.g., as generated by site-directed mutagenesis or another method of producing mutations in a nucleotide sequence). The prey populations are proteins encoded by DNA (e.g., cDNA, genomic DNA or synthetically generated DNA), said DNAs derived either from a specific gene of choice, or from cDNA libraries obtain from a cell type of interest. 15 For example, the populations may be expressed from chimeric genes comprising cDNA sequences derived from a non-characterized sample of a population of cDNA from mammalian RNA. In another specific embodiment, recombinant biological libraries expressing random peptides may be used as the source of prey nucleic acids. The present invention discloses methods for the screening for inhibitors of HsLON. In brief, the 20 protein-protein interaction assay may be performed as previously described herein, with the exception that it is performed in the presence of one or more candidate molecules. A resulting alteration in level of Reporter Gene activity, in relation to that level which was present when the one or more candidate molecules are absent, indicates that the candidate molecule exerts an effect on the interacting pair. In a preferred embodiment, inhibition of the protein interaction is necessary for the yeast cells to survive, for 25 example, where a non-attenuated protein interaction causes the activation of the URA3 gene, causing yeast to die in medium containing the chemical 5-fluoroorotic acid. See e.g., Rothstein, 1983. Meth. Enzymol. 101: 167-180. In general, the proteins comprising the bait and prey populations are provided as fusion (chimeric) proteins, preferably by recombinant expression of a chimeric coding sequence containing 30 each protein contiguous to a pre-selected sequence. For one population, the pre-selected sequence is a DNA-binding domain that may be any DNA-binding domain, so long as it specifically recognizes a DNA sequence within a promoter (e.g., a transcriptional activator or inhibitor). For the other population, the pre-selected sequence is an activator or inhibitor domain of a transcriptional activator or inhibitor, respectively. The regulatory domain alone (not as a fusion to a protein sequence) and the WO 00/02911 PCT/US99/15592 -42 DNA-binding domain alone (not as a fusion to a protein sequence), preferably, do not detectably interact, so as to avoid false-positives in the assay. The assay system further includes a reporter gene operably linked to a promoter that contains a binding site for the DNA-binding domain of the transcriptional activator (or inhibitor). Accordingly, in the practice of the present invention, the binding 5 of p-APP fusion protein to a prey fusion protein leads to reconstitution of a transcriptional activator (or inhibitor), which concomitantly alters expression of the Reporter Gene. In a specific embodiment, the present invention discloses a methodology for detecting one or more protein-protein interactions comprising the following steps: (i) recombinantly-expressing -APP (or a derivative, fragment, analog or homolog thereof) in a first population of yeast cells of a first mating 0 type and possessing a first fusion protein containing 1-APP sequence and a DNA-binding domain; wherein said first population of yeast cells contains a first nucleotide sequence operably-linked to a promoter that is "driven" by one or more DNA-binding sites recognized by said DNA-binding domain such that an interaction of said first fusion protein with a second fusion protein (comprising a transcriptional activation domain) results in increased transcription of said first nucleotide sequence; 5 (ii) negatively selecting to eliminate those yeast cells in said first population in which said increased transcription of said first nucleotide sequence occurs in the absence of said second fusion protein; (iii) recombinantly expressing in a second population of yeast cells of a second mating type different from said first mating type, a plurality of said second fusion proteins; wherein said second fusion protein is comprised of a sequence of a derivative, fragment, analog or homolog of a HsLON and an activation 0 domain of a transcriptional activator, in which the activation domain is the same in each said second fusion protein; (iv) mating said first population of yeast cells with said second population of yeast cells to form a third population of diploid yeast cells, wherein said third population of diploid yeast cells contains a second nucleotide sequence operably linked to a promoter "driven" by a DNA-binding site recognized by said DNA-binding domain such that an interaction of a first fusion protein with a second 5 fusion protein results in increased transcription of said second nucleotide sequence, in which the first and second nucleotide sequences can be the same or different and (v) detecting said increased transcription of said first and/or second nucleotide sequence, thereby detecting an interaction between a first fusion protein and a second fusion protein. In a preferred embodiment, the bait (a 1-APP sequence) and the prey (a library of chimeric 0 genes) are combined by mating the two yeast strains on solid media for a period of approximately 6-8 hours. In a less preferred embodiment, the mating is performed in liquid media. The resulting diploids contain both types of chimeric genes (i.e., the DNA-binding domain fusion and the activation domain fusion). After an interactive population is obtained, the DNA sequences encoding the pairs of interactive proteins are isolated by a method wherein either the DNA-binding domain hybrids or the WO 00/02911 PCTIUS99/15592 -43 activation domain hybrids are amplified, in separate reactions. Preferably, the amplification is carried out by polymerase chain reaction (PCR; see e.g., Innis, et al., 1990. PCR PROTOCOLS, Academic Press, Inc., San Diego, CA) utilizing pairs of oligonucleotide primers specific for either the DNA-binding domain hybrids or the activation domain hybrids. The PCR amplification reaction may also be 5 performed on pooled cells expressing interacting protein pairs, preferably pooled arrays of interactants. Other amplification methods known within the art may also be used including, but not limited to, ligase chain reaction; Qp-replicase or the like. See e.g., Kricka, et al., 1995. MOLECULAR PROBING, BLOTTING, AND SEQUENCING, Academic Press, New York, NY. In an additional embodiment of the present invention, the plasmids encoding the DNA-binding 10 domain hybrid and the activation domain hybrid proteins may also be isolated and cloned by any of the methods well-known within the art. For example, but not by way of limitation, if a shuttle vector (for e.g., yeast to E. coli) is used to express the fusion proteins, the genes may be subsequently recovered by transforming the yeast DNA into E. coli and recovering the plasmids from the bacteria. See e.g., Hoffman, et al., 1987 Gene 57: 267-272. 15 Pharmaceutical Compositions The invention provides methods of treatment and prophylaxis by the administration to a subject of a pharmaceutically-effective amount of a Therapeutic of the invention. In a preferred embodiment, the Therapeutic is substantially purified and the subject is a mammal, and most preferably, human. Formulations and methods of administration that can be employed when the Therapeutic 20 comprises a nucleic acid are described supra. Various delivery systems are known and can be used to administer a Therapeutic of the present invention including, but not limited to: (i) encapsulation in liposomes, microparticles, microcapsules; (ii) recombinant cells capable of expressing the Therapeutic; (iii) receptor-mediated endocytosis (see, e.g., Wu & Wu, 1987. J. Bio. Chem. 262: 4429-4432); (iv) construction of a Therapeutic nucleic acid as part of a retroviral or other vector, and the like. 25 Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The Therapeutics of the present invention may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically-active agents. 0 Administration can be systemic or local. In addition, it may be advantageous to administer the Therapeutic into the central nervous system by any suitable route, including intraventricular and intrathecal injection. Intraventricular injection may be facilitated by an intraventricular catheter attached WO 00/02911 PCT/US99/15592 -44 to a reservoir (e.g., an Ommaya reservoir). Pulmonary administration may also be employed by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. It may also be desirable to administer the Therapeutic locally to the area in need of treatment. This may be achieved by, for example, and not by way of limitation, by local infusion during surgery, by topical application, by 5 injection, by means of a catheter, by means of a suppository, or by means of an implant. In a specific embodiment, administration may be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue. In another embodiment of the present invention, the Therapeutic may be delivered in a vesicle, in particular a liposome. See e.g., Langer, 1990. Science 249: 1527-1533. In yet another embodiment, 10 the Therapeutic can be delivered in a controlled release system including, but not limited to, a delivery pump (see e.g., Saudek, et al., 1989. New Engl. J. Med. 321: 574) and a semi-permeable polymeric material (see e.g., Howard, et al., 1989. J. Neurosurg. 71: 105). Additionally, the controlled release system can be placed in proximity of the therapeutic target (e.g., the brain), thus requiring only a fraction of the systemic dose. See, e.g., Goodson, In: MEDICAL APPLICATIONS OF CONTROLLED 15 RELEASE, CRC Press, Bocca Raton, FL (1984). In a specific embodiment, where the Therapeutic is a nucleic acid encoding a protein, the Therapeutic nucleic acid may be administered in vivo to promote expression of its encoded protein by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular (e.g., via a retroviral vector, direct injection, use of microparticle bombardment, 20 coating with lipids or cell-surface receptors or transfecting agents, or administering it in linkage to a homeobox-like peptide that is known to enter the nucleus (see e.g., Joliot, et al., 1991. Proc. NatL. Acad. Sci. USA 88: 1864-1868), and the like. Alternatively, a nucleic acid Therapeutic can be introduced intracellularly and incorporated into host cell DNA for expression, e.g., by homologous recombination. The present invention also provides pharmaceutical compositions. Such compositions comprise 25 a therapeutically-effective amount of Therapeutic, and a pharmaceutically acceptable carrier. As utilized herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government, or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals and, more particularly, in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered and includes, but is 30 not limited, to such sterile liquids as water and oils. The amount of the Therapeutic of the invention that will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and may be determined by standard clinical techniques by those of average skill within the art. In addition, in vitro WO 00/02911 PCT/US99/15592 -45 assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration and the overall seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and of each patient's circumstances. However, suitable dosage ranges for intravenous administration of a 5 Therapeutics herein are generally about 20-500 micrograms (pg) of active compound per kilogram (kg) body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 picograms (pg)/kg body weight to 1 milligram (mg)/kg body weight. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10 10% to 95% active ingredient. The present invention also provides a pharmaceutical pack or kit, comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions and Therapeutics of the present invention. Optionally associated with such container(s) may be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of 15 pharmaceutical or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration. SPECIFIC EXAMPLES Example 1: Identification and specificity of p-APP:HsLON interaction A modified, improved yeast two hybrid system was used to identify protein interactions for the 20 neuronal protein product n-APP. Yeast is an eukaryote, and therefore any intermolecular protein interactions detected in this system are likely to occur under physiological conditions found in mammalian cells (Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9581). Expression vectors were constructed to encode two hybrid proteins. One hybrid consists of the DNA binding domain of the yeast transcriptional activator Gal4 fused to a predetermined "bait" polypeptide. The other hybrid 25 consisted of the Gal4 activator domain fused to "prey" polypeptide sequences encoded by a mammalian cDNA library. In a "reverse" screen, the bait was fused to the activator domain, and the prey was fused to the DNA binding domain, but the assay was otherwise identically performed. In a matrix-mating assay, P-APP, HsLON, and other proteins were inserted into complementary (a and alpha) mating types of yeast using methods known in the art. Mating was carried out to express both vector constructs 30 within the same yeast cells, thus allowing interaction to occur. Interaction between the domains led to transcriptional activation of reporter genes containing cis-binding elements for Gal4. The reporter genes encoding the indicator protein fp-galactosidase, and metabolic markers for uracil and histidine auxotrophy, were included in specific fashion in one or the other of the yeast strains used in the mating.

WO 00/02911 -46- PCT/US99/15592 In this way, yeast were selected for successful mating, expression of both fusion constructs, and expression of p-APP-interacting proteins and the interaction of both fusion proteins. The HsLON cDNA were obtained from a commercial fetal brain cDNA library of 3.5 x 106 independent isolates (Clontech #HL4029AH, Palo Alto, CA). The library was synthesized from Xho 5 1-dT 5 primed fetal brain mRNA (from five male/female 19-22 week fetuses) that was directionally cloned into pACT2, a yeast Gal4 activation domain cloning vector including the LEU2 gene for selection in yeast deficient in leucine biosynthesis. Interaction of the prey cDNA products was tested against an array of 18 bait proteins, one of which was encoded by the p-APP gene sequence from nucleotide 1935 to 2060, which encodes p-APP 0 695 residues 597-638, commonly known as the 42 residue peptide p-A4(42). The bait fragment was amplified from the Clontech pACT2 library (Clontech, Palo Alto, CA) by polymerase chain reaction (PCR) using the forward primer 5'GATGCAGAATTCCGACATGACTCAG3' (SEQ ID NO:5) and the reverse primer 5'ATGGTGGGCGGTGTTGTCATAGCG3' (SEQ ID NO:6) by standard techniques. The fragment was cloned into the Sf1i site of the vector pAS-SfiI, constructed by introducing an 5 Sfi1-containing polylinker into the vector pAS2-1 (Clontech, Palo Alto, CA). This vector is a yeast DNA-binding domain cloning vector that contains the TRP1 gene for selection in yeast strains deficient in tryptophan biosynthesis. The bait sequence was confirmed by nucleic acid sequencing to confirm that PCR amplification reproduced an accurate copy of the p-APP sequence (Figure 1, SEQ ID NO: 1). This test determined that, as predicted, the bait sequence encoded an interacting domain identical to the 0 human P-A4 peptide of 42 amino acids. Example 2: Test for the specificity of f3-APP:HsLON interaction p-APP was transformed by lithium acetate/polyethylene glycol transformation (Ito et al., 1983, J. Bacteriol. 153: 163-168) into the yeast strain N106' (mating type a, ura3, his3, ade2, trpl, leu2, gal4, gal80, cyh', Lys 2 ::GAL]uArHIS37A7A-HIS3, ura 3::GALJuArGALAm-lacZ), while the coding sequences 5 of HsLON were transformed into the yeast strain YULH (mating type alpha, ura3, his3, lys2, trpl, leu2, gal4, gal8O, GAL1-URA3). The two transformed populations were then mated using standard methods in the art. Sherman et al., eds., 1991, GETTING STARTED WITH YEAST, Vol. 194, Academic Press, New York. Briefly, cells were grown until mid-to-late log phase on media that selected for the presence of the appropriate plasmids. The two mating strains, alpha and a, were then, diluted in YAPD media, 0 filtered onto nitrocellulose membranes, and incubated at 300 C for 6-8 hours. The cells were then transferred to media selective for the desired diploids, i.e., yeast harboring reporter genes for P-galactosidase, uracil auxotrophy, and histidine auxotrophy, and expression of the vectors encoding the bait and prey. The mating products were plated on SC (synthetic complete) (Sambrook et al., 1989, A WO 00/02911 47 PCT/US99/15592 LABORATORY MANUAL, 2 nd Ed., Cold Spring Harbor Press, New York) media lacking adenine and lysine (to select for successful mating), leucine and tryptophan (to select for expression of genes encoded by both plasmids), and uracil and histidine (to select for protein interactions). This medium is herein referred to as SCS medium, for SC Selective medium. 5 Selected clones were tested for expression of p-galactosidase to confirm the formation of a fp-APP:HsLON complex. Filter-lift p-galactosidase assays were performed as modified from the protocol of Breeden and Nasmyth, 1985, Cold Spring Harbor Quant. Biol. 50: 643-650. Colonies were patched onto SCS plates, grown overnight, and replica plated onto nitrocellulose filters. The filters were then assayed for f3-galactosidase activity as per Breeden and Nasmyth, 1985, Cold Spring Harbor Quant. 10 Biol. 50: 643-650. Colonies that were positive turned a visible blue. To test for the specificity of p-APP:HsLON interaction, two general tests were first performed. In the first instance, YULH cells expressing HsLON were created and plated on SC-Ura plates, grown for 1-2 days, and examined for growth. No growth was found for HsLON, confirming that it is not a "self-activating" protein, that is, HsLON requires interaction with a second protein domain for a 15 functional activation complex. In the second instance, plasmids containing P-APP inserts were transformed into strain N106' (mating type alpha) and mated with yeast strain YULH (mating type a) expressing either CDK2, HsLON, or certain other proteins. Promiscuous binders, that is, insert products able to bind with many other proteins in a non-specific fashion, would interact non-specifically with non-CDK2 domains, and would be discarded as non-specific interactants. As illustrated in Figure 3, the 20 intersection of the p-APP column with the HsLON row indicates growth (Box A) (i.e., a positive interaction). In contrast, the intersection of the fp-APP column with the rows for P1 - P5, and the intersection of the HsLON row with columns for BI - B6, indicates no growth, i.e., no protein interaction. These data demonstrate the specificity of the fp-APP:HsLON interaction. The present invention is not to be limited in scope by the specific embodiments described 25 herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Various publications are cited herein, the disclosures of which are incorporated by reference in their entirety.

WO 00/02911 PCT/US99/15592 -48 EQUIVALENTS From the foregoing detailed description of the specific embodiments of the invention, it should be apparent that unique compositions and methods of use for f-APP, HsLON, and p-APP:HsLON complexes have been described. Although particular embodiments have been disclosed herein in detail, 5 this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims which follow. In particular, it is contemplated by the inventor that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. For instance, the choice of disease states in which f3-APP, HsLON, and p-APP:HsLON complexes provide utility through 10 diagnosis, screening, treatment of various diseases and disorders is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein.

Claims (64)

1. A purified complex of 3-APP and HsLON.

2. The purified complex of claim 1 in which the proteins are human proteins.

3. A purified complex selected from the group consisting of a complex of a derivative of p-APP and HsLON, a complex of p-APP and a derivative of HsLON, and a complex of a derivative of p-APP and a derivative of HsLON; in which the derivative of p-APP is able to form a complex with a wild-type HsLON and the derivative of HsLON is able to form a complex with wild-type p-APP.

4. The purified complex of claim 3 in which the derivative of B-APP or HsLON is fluorescently labeled.

5. A chimeric protein comprising a fragment of p-APP consisting of at least 6 amino acids fused via a covalent bond to a fragment of HsLON consisting of at least 6 amino acids.

6. The chimeric protein of claim 5 in which the fragment of p-APP is a fragment capable of binding HsLON and in which the fragment of HsLON is a fragment capable of binding p-APP.

7. The chimeric protein of claim 6 in which the fragment of fp-APP and the fragment of HsLON form a f3-APP:HsLON complex.

8. An antibody which immunospecifically binds the complex of claim I or a fragment or derivative of said antibody containing the binding domain thereof.

9. The antibody of claim 8 which does not immunospecifically bind p-APP or HsLON that is not part of a p-APP:HsLON complex.

10. An isolated nucleic acid or an isolated combination of nucleic acids comprising a nucleotide sequence encoding p-APP and a nucleotide sequence encoding HsLON.

11. The isolated nucleic acid or isolated combination of nucleic acids of claim 10 which are nucleic acid vectors.

12. The isolated nucleic acid or isolated combination of nucleic acids of claim 11 in which the 1-APP coding sequence and the HsLON coding sequence are operably linked to a promoter.

13. An isolated nucleic acid that comprises a nucleotide sequence encoding the chimeric protein of claim 7. WO 00/02911 PCT/US99/15592 -50

14. A cell containing a nucleic acid of claim 10, which nucleic acid is recombinant.

15. A cell containing a nucleic acid of claim 12, which nucleic acid is recombinant.

16. A recombinant cell containing a nucleic acid of claim 15, which nucleic acid is recombinant.

17. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the complex of claim 1; and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 in which the proteins are human proteins.

19. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the complex of claim 3; and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the chimeric protein of claim 5; and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition of comprising a therapeutically or prophylactically effective amount of the chimeric protein of claim 6; and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the antibody of claim 8 or a fragment or derivative of said antibody containing the binding domain thereof; and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the antibody of claim 9 or a fragment or derivative of said antibody containing the binding domain thereof; and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the nucleic acid or combination of nucleic acids of claim 10; and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the isolated nucleic acid of claim 13; and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the recombinant cell of claim 14; and a pharmaceutically acceptable carrier. WO 00/02911 PCT/US99/15592 -51

27. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the protein of claim 15; and a pharmaceutically acceptable carrier.

28. A method of producing a complex of f3-APP and HsLON comprising growing a recombinant cell containing the nucleic acid of claim 10 such that the encoded 13-APP and HsLON proteins are expressed and bind to each other, and recovering the expressed complex of p-APP and HsLON.

29. A method of diagnosing or screening for the presence of or a predisposition for developing a disease or disorder characterized by an aberrant level of a complex of p-APP and HsLON, in a subject comprising measuring the level of said complex, RNA encoding P-APP and HsLON, or functional activity of said complex in a sample derived from the subject, in which an increase or decrease in the level of said complex, said RNA encoding p-APP and HsLON, or functional activity of said complex in the sample, relative to the level of said complex, said RNA encoding p-APP and HsLON or functional activity of said complex found in an analogous sample not having the disease or disorder or a predisposition for developing the disease or disorder, indicates the presence of the disease or disorder or a predisposition for developing the disease or disorder.

30. A kit comprising in one or more containers a substance selected from the group consisting of a complex of f-APP and HsLON, an antibody against said complex, nucleic acid probes capable of hybridizing to RNA of p-APP and RNA of HsLON, or pairs of nucleic acid primers capable of priming amplification of at least a portion of the p-APP gene and the HsLON gene.

31. A method of treating or preventing a disease or disorder involving aberrant levels of a complex of 1-APP and HsLON, in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule or molecules that modulate the function of said complex.

32. The method of claim 31 in which said disease or disorder involves decreased levels of said complex and said molecule or molecules promote the function of the complex of 1-APP and HsLON and are selected from the group consisting of a complex of 13-APP and HsLON; a derivative or analog of a complex of 13-APP and HsLON, which complex is more stable or more active than the wild type complex; nucleic acids encoding p-APP and HsLON proteins; and nucleic acids encoding a derivative or analog of 1-APP and HsLON that form a complex that is more stable or more active than the wild type complex. WO 00/02911 PCTIUS99/15592 -52

33. The method of claim 31 in which said disease or disorder involves increased levels of said complex and said molecule or molecules inhibit the function of said complex and are selected from the group consisting of an antibody against said complex or a fragment or derivative thereof containing the binding region thereof; P-APP and HsLON antisense nucleic acids; and nucleic acids comprising at least a portion of the p-APP and the HsLON gene into which a heterologous nucleotide sequence has been inserted such that said heterologous sequence inactivates the biological activity of the at least a portion of the p-APP and HsLON genes, in which the p-APP and the HsLON gene portions flank the heterologous sequences so as to promote homologous recombination with genomic p-APP and HsLON genes.

34. A method of treating or preventing a disease or disorder involving an aberrant level of HsLON in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of HsLON.

35. The method of claim 34 in which said disease or disorder involves a decreased level of HsLON and said molecule promotes the function of HsLON and is selected from the group consisting of the HsLON protein, derivative or analog of HsLON that is active in binding p-APP, a nucleic acid encoding HsLON, and a nucleic acid encoding a derivative or analog of HsLON that is active in binding p3-APP.

36. The method of claim 34 in which said disease or disorder involves an increased level of HsLON and said molecule inhibits HsLON function and is selected from the group consisting of an anti-HsLON antibody or a fragment or derivative thereof containing the binding region thereof, a HsLON antisense nucleic acid, and a nucleic acid comprising at least a portion of the HsLON gene into which a heterologous nucleotide sequence has been inserted such that said heterologous sequence inactivates the biological activity of the at least a portion of the HsLON gene, in which the HsLON gene portion flanks the heterologous sequence so as to promote homologous recombination with the genomic HsLON gene.

37. A method of treating or preventing a disease or disorder involving an aberrant level of 1-APP in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of P-APP. WO 00/02911 PCT/US99/15592 -53

38. The method of claim 37 in which said disease or disorder involves a decreased level of 3-APP and said molecule promotes the function of P-APP and is selected from the group consisting of the fp-APP protein, derivative or analog of 13-APP that is active in binding HsLON, a nucleic acid encoding p-APP, and a nucleic acid encoding a derivative or analog of p-APP that is active in binding HsLON.

39. The method of claim 37 in which said disease or disorder involves an increased level of p-APP and said molecule inhibits 1-APP function and is selected from the group consisting of an anti-p-APP antibody or a fragment or derivative thereof containing the binding region thereof, a 1-APP antisense nucleic acid, and a nucleic acid comprising at least a portion of the 13-APP gene into which a heterologous nucleotide sequence has been inserted such that said heterologous sequence inactivates the biological activity of the at least a portion of the 1-APP gene, in which the P-APP gene portion flanks the heterologous sequence so as to promote homologous recombination with the genomic p-APP gene.

40. A method for screening a purified complex of p-APP and HsLON, or a derivative of said complex, or a modulator of the activity of said complex for activity in treating or preventing neurodegenerative disease comprising contacting cultured cells that exhibit an indicator of neurodegenerative disease in vitro with said complex, derivative or modulator; and comparing the level of said indicator in the cells contacted with the complex, derivative, or modulator with said level of said indicator in cells not so. contacted, wherein a lower level in said contacted cells indicates that the complex, derivative or modulator has activity in treating or preventing neurodegenerative disease.

41. A method for screening a purified complex of 13-APP and HsLON, or a derivative of said complex, or a modulator of the activity of said complex for activity in treating or preventing an cardiomyopathy comprising contacting cultured cells that exhibit an indicator of a cardiomyopathy in vitro with said complex, derivative or modulator; and comparing the level of said indicator in the cells contacted with the complex, derivative, or modulator with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the complex, derivative or modulator has activity in treating or preventing cardiomyopathy. WO 00/02911 PCT/US99/15592 -54

42. A method for screening a purified complex of p-APP and HsLON, or a derivative of said complex, or a modulator of the activity of said complex for activity in treating or preventing a diabetes comprising contacting cultured cells that exhibit an indicator of a diabetes in vitro with said complex, derivative or modulator; and comparing the level of said indicator in the cells contacted with the complex, derivative, or modulator with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the complex, derivative or modulator has activity in treating or preventing diabetes.

43. A method for screening a purified complex of p-APP and HsLON, or a derivative of said complex, or a modulator of the activity of said complex for activity in treating or preventing a hearing loss comprising contacting cultured cells that exhibit an indicator of a hearing loss in vitro with said complex, derivative or modulator; and comparing the level of said indicator in the cells contacted with the complex, derivative, or modulator with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the complex, derivative or modulator has activity in treating or preventing hearing loss.

44. A method for screening a purified complex of p-APP and HsLON, or a derivative of said complex, or a modulator of the activity of said complex for activity in treating or preventing male infertility comprising contacting cultured cells that exhibit an indicator of a male infertility in vitro with said complex, derivative or modulator; and comparing the level of said indicator in the cells contacted with the complex, derivative, or modulator with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the complex, derivative or modulator has activity in treating or preventing male infertility.

45. A method for screening a purified complex of p-APP and HsLON, or a derivative of said complex, or a modulator of the activity of said complex for activity in treating or preventing mitochondrial DNA mutation associated disorders comprising contacting cultured cells that exhibit an indicator of a mitochondrial DNA mutation associated disorders in vitro with said complex, derivative or modulator; and comparing the level of said indicator in the cells contacted with the complex, derivative, or modulator with said level of said indicator in cells not so contacted, wherein a lower level in said contacted cells indicates that the complex, derivative or modulator has activity in treating or preventing mitochondrial DNA mutation associated disorders. WO 00/02911 PCT/US99/15592 -55

46. A method of screening for a molecule that modulates directly or indirectly the formation of a complex of p-APP and HsLON comprising measuring the levels of said complex formed from fp-APP and HsLON proteins in the presence of said molecule under conditions conducive to formation of the complex; and comparing the levels of said complex with the levels of said complex that are formed in the absence of said molecule, wherein a lower or higher level of said complex in the presence of said molecule indicates that the molecule modulates formation of said complex.

47. A recombinant non-human animal in which both an endogenous p-APP gene and an endogenous HsLON have been deleted or inactivated by homologous recombination or insertional mutagenesis of said animal or an ancestor thereof.

48. A recombinant non-human animal containing both a P-APP gene and a HsLON gene, in which the P-APP gene is under the control of a promoter that is not the native 3-APP gene promoter and the HsLON gene is under the control of a promoter that is not the native HsLON gene promoter.

49. A recombinant non-human animal containing a transgene comprising a nucleic acid sequence encoding the chimeric protein of claim 7.

50. A method of modulating the activity or levels of p-APP by contacting a cell with, or administering an animal expressing a p-APP gene, a HsLON protein, or a nucleic acid encoding said protein or an antibody that immunospecifically binds said protein or a fragment or derivative of said antibody containing the binding domain thereof.

51. A method of modulating the activity or levels of HsLON by contacting a cell with, or administering an animal expressing a gene encoding said protein, p-APP, or a nucleic acid encoding f-APP, or an antibody that immunospecifically binds p-APP or a fragment or derivative of said antibody containing the binding domain thereof.

52. A method of modulating the activity or levels of a complex of p-APP and HsLON by contacting a cell with, or administering an animal expressing and forming said complex, a molecule that modulates the formation of said complex.

53. A method for identifying a molecule that modulates activity of 1-APP or HsLON or a complex of P-APP and HsLON comprising contacting one or more candidate molecules with f3-APP in the presence of HsLON; and measuring the amount of complex that forms between p-APP and HsLON; wherein an increase or decrease in the amount of complex that forms relative to the amount that forms in the absence of the candidate molecules indicates-that the molecules modulate the activity of 1-APP or HsLON or said complex of p-APP and HsLON. WO 00/02911 PCT/US99/15592 -56

54. The method of claim 53 wherein said contacting is carried out by administering the candidate molecules to the recombinant non-human animal of claim 49.

55. The method of claim 54 wherein said contacting is carried out in vitro; and fp-APP, HsLON, and said candidate molecules are purified.

56. A method for screening a derivative or analog of p-APP for biological activity comprising contacting said derivative or analog of [-APP with HsLON; and detecting the formation of a complex between said derivative or analog of p-APP and HsLON; wherein detecting formation of said complex indicates that said derivative or analog of [-APP has biological activity.

57. A method for screening a derivative or analog of HsLON for biological activity comprising contacting said derivative or analog of HsLON with p-APP; and detecting the formation of a complex between said derivative or analog of HsLON and p-APP; wherein detecting the formation of said complex indicates that said derivative or analog of HsLON has biological activity.

58. A method of monitoring the efficacy of a treatment of a disease or disorder characterized by an aberrant level of a complex of [-APP and HsLON in a subject administered said treatment for said disease or disorder comprising measuring the level of said complex, RNA encoding [-APP and HsLON, or functional activity of said complex in a sample derived from said subject wherein said sample is taken from said subject after the administration of said treatment and compared to (a) said level in a sample taken from said subject prior to the administration of the treatment or (b) a standard level associated with the pretreatment stage of the disease or disorder, in which the change, or lack of change in the level of said complex, said RNA encoding p-APP and HsLON, or functional activity of said complex in said sample taken after the administration of said treatment relative to the level of said complex, said RNA encoding [3-APP and HsLON or functional activity of said complex in said sample taken before the administration of said treatment or to said standard level indicates whether said administration is effective for treating said disease or disorder.

59. A method of treating or preventing neurodegeneration in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of a complex of p-APP and HsLON.

60. A method of treating or preventing cardiomyopathy in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of a complex of p-APP and HsLON. WO 00/02911 PCTIUS99/15592 -57

61. A method of treating or preventing diabetes in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of a complex of f3-APP and HsLON.

62. A method of treating or preventing hearing loss in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of a complex of p-APP and HsLON.

63. A method of treating or preventing male infertility or an associated disease in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of a complex of p-APP and HsLON.

64. A method of treating or preventing mitochondrial DNA mutation or an associated disease in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that modulates the function of a complex of p-APP and HsLON.